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30Kc19 protein is a member of the 30K protein family, a similar structured 
protein found in hemolymph of Bombyx mori. These proteins have molecular 
weights of around 30 kDa, and 30Kc19 protein is the most abundant among 
30K proteins (30Kc6, 30Kc12, 30Kc19, 30Kc21 and 30Kc23) in the 
hemolymph. Although the biological functions of the 30K proteins in silkworms 
have not been fully determined, several studies have recently examined their 
functional properties for 30Kc6 and 30Kc19. In previous studies, it was 
demonstrated that silkworm hemolymph and 30K proteins exhibit an anti-
apoptotic effect in various cells by adding the protein to culture medium or by 




erythropoietin, interferon-, and monoclonal antibody, as well as increasing 
glycosylation, cell growth, and viability in various cells, and also had enzyme-
stabilizing effects. A recent study has shown that 30Kc19 protein has a cell-
penetrating property when supplemented to the culture medium. Therefore, 
30Kc19 protein is a very unique multi-functional protein, and can be applied for 
the delivery of therapeutic proteins, including enzymes, as it can penetrate cell 
membrane as well as stabilizing cargo proteins. 
The dimerization propensity of the 30Kc19 in the presence of amphiphiles 
led to the objective of this research; the investigation on the mechanism of 
internalization of the 30Kc19 and the minimal effective partial sequence of the 
parent protein that is necessary for the cell-penetrating to occur and delivery of 
cargos into cells. First, dimerization propensity of the 30Kc19 protein in the 
presence of amphiphilic moieties; SDS and phospholipid was investigated. 
Native PAGE result showed that the 30Kc19 monomer formed a dimer when 
SDS or phospholipid was present. From the GST pull-down assay, 
supplementation of the 30Kc19 protein to mammalian cell culture medium 
showed dimerization and penetration; due to phospholipids at the cell 
membrane, the main components of the lipid bilayer. Mutagenesis was 
performed, and penetration was observed by 30Kc19 C76A and not 30Kc19 
C57A, which meant Cys-57 is involved in dimerization of the 30Kc19 at the 
cell membrane during penetration. Then explored how the cell-penetrating 
30Kc19 protein is related with phospholipids, the main cell membrane 
components, and elucidate the mechanism of entry of the 30Kc19 protein into 




Based on the cell penetrating mechanism and cargo-delivery ability, 
hypothetical presence of cell-penetrating peptide (CPP) was assumed and 
endeavored in the identification of a CPP of the 30Kc19 protein originating 
from the silkworm. For the practical use in delivery of cell-impermeable cargo 
molecules, it is necessary to find a cell-penetrating domain like other cell-
penetrating proteins that can efficiently deliver cargo molecules into cells. A 
domain was selected as the most probable candidate for CPP and several CPP 
candidates were tested for cell-penetrating property. From this, a new CPP; 
VVNKLIRNNKMNC, from 30Kc19 protein (Pep-c19) was identified and 
demonstrated that 30Kc19 exhibited a cell-penetrating property due to the 
presence of a cell-penetrating peptide at 45-57. Efficiency and toxicity of this 
CPP was investigated in comparison with its original protein, 30Kc19, both in 
vitro and in vivo and showed its superiority over its parent protein in terms of 
efficiency. Pep-c19 is a cell-penetrating peptide derived from the first cell-
penetrating protein in insect hemolymph. Through this finding, anticipate in 
finding other cell-penetrating peptides from other proteins sourced from insects 
that have similar properties to Pep-c19. 
For therapeutic application, non-covalent approach for the delivery of siRNA. 
The results showed that Pep-c19 was able to deliver siRNAs and have gene 
silencing effect along with 11R, other widely recognized CPP.  
The 30Kc19 protein and Pep-c19 are a non-virus derived (e.g. TAT) and non-
cytotoxic cell-penetrating protein/peptide. This study may open up new 
approaches and provide beneficial effects for the delivery of therapeutics in 
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Chapter 1. Research background and objectives 
The 30Kc19 protein, a member of the 30K protein family, is a similar 
structured protein found in silkworm hemolymph, Bombyx mori [1]. It is the 
most abundant among 30K proteins (30Kc6, 30Kc12, 30Kc19, 30Kc21 and 
30Kc23) in hemolymph with molecular weights of about 30 kDa [2]. These 
“30K proteins” are synthesized in fat body cells and accumulate in the 
hemolymph during the fifth instar larval to early pupal stages [3, 4]. They are 
then transferred from the hemolymph to fat body cells during metamorphosis 
from larva to pupa and are deposited there until use [5, 6]. 
The biological functions of the 30K proteins in silkworms have not been 
fully determined, although several studies have recently examined their 
functional properties [6, 7]. In previous studies, it was demonstrated that 
silkworm hemolymph and 30K proteins exhibit an anti-apoptotic effect in 
various cells by adding the protein to culture or medium by gene expression [8-
20]. Other than the anti-apoptotic effect, 30K proteins also enhance production 
of recombinant erythropoietin, interferon-, and monoclonal antibodies; 
increase glycosylation, cell growth, and viability in various cells; and have an 
enzyme-stabilizing effect [21-28]. A recent study has shown that 30Kc19 
protein has a cell-penetrating property when supplemented to the culture 
medium [29]. Therefore, the 30Kc19 protein is a very unique multifunctional 
protein that can be applied for the delivery of therapeutic proteins including 
enzymes, as it can penetrate cell membranes and stabilize cargo proteins. 
However, the exact mechanism of penetration to animal cells has not been fully 
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determined and hence is necessary to understand the molecular mechanism of 
cell penetration for the practical use of the 30Kc19 protein. In addition, for the 
practical use in delivery of cell-impermeable cargo molecules, it is necessary to 
find a cell-penetrating domain like other cell-penetrating proteins that can 
efficiently deliver cargo molecules into cells. 
In this research, dimerization propensity of the 30Kc19 protein in the 
presence of amphiphilic moieties; SDS and phospholipid was investigated. 
Then explored how the cell-penetrating 30Kc19 protein is related with 
phospholipids, the main cell membrane components, and elucidate the 
mechanism of entry of the 30Kc19 protein into animal cells for use in protein 
delivery system. Furthermore, I endeavored in the identification of a cell-
penetrating peptide of the 30Kc19 protein (Pep-c19), originating from the 
silkworm. A domain was selected as the most probable candidate for CPP and 
several CPP candidates were tested for cell-penetrating property. Then, 
efficiency and toxicity of this CPP was investigated in comparison with its 
original protein, 30Kc19, both in vitro and in vivo.  
 
In summary, the objectives of this study are:  
 
1. Investigation of dimerization propensity of the 30Kc19 protein in the 
presence of amphiphilic moieties and the mechanism of entry into 
mammalian cells. 
2. Prediction and identification of cell-penetrating peptide (CPP) of the 
30Kc19 protein (Pep-c19) 
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3. Application of Pep-c19 for protein delivery in vitro and in vivo systems 
4. Application of Pep-c19 for siRNA delivery in vitro system 
 
The 30Kc19 protein and Pep-c19 are a non-virus derived (e.g. TAT) and non-
cytotoxic (polyarginine) cell-penetrating protein/peptide. In this study, efforts 
have led to finding of cell-penetrating mechanism of the 30Kc19 protein and its 
relationship with dimerization phenomenon, identification of Pep-c19 for 
protein delivery in vitro and in vivo, and its potential for therapeutic protein 
delivery. This study may open up new approaches for the delivery of 




























Chapter 2. Literature review 
2.1 Cell-penetrating peptides (CPPs) 
Biological molecules, including proteins, small molecules, nucleic acids, 
antibodies, nanoparticles, and drugs enter into the cells through lipid bilayer or 
the nucleus across nuclear membrane to utilize their given actions in the cells. 
Generally however, cell membrane restricts intracellular and intranuclear 
delivery of molecules except for certain circumstances and specific conditions. 
To overcome problems of conventional intracellular delivery, various 
techniques have been developed. A conventional procedure for delivering 
genetic material is to use viral vectors, but treating genetic disorders with this 
method has met with only limited success [30]. Alternative nonviral methods, 
such as electroporation, microinjection, pH-sensitive or cationic liposomes have 
been developed for conventional drug delivery. However, limitations in terms of 
efficiency, applicable to only some molecules, or requirement of special tools 
were shown [31-33].  
 
2.1.1 Terminology, classification, and structure of CPPs 
A unified terminology and classification of the carrier peptides has not yet 
been developed. In the past two decades, as well as cell-penetrating proteins, 
the so-called “cell-penetrating peptides (CPPs)” have gained increasing 
attention. These new class of peptides are generally less than 30 amino acids in 
length, and are comprised of cationic and/or hydrophobic residues, which can 
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penetrate into cells [34, 35]. In 1988, Green and Frankel first discovered that 
TAT CPP derived from HIV-1 virus move across the cell membrane [36, 37]. 
They demonstrated the ability of TAT protein, derived from human 
immunodeficiency virus-1 (HIV-1), to penetrate into cells in a receptor-
independent and concentration-dependent manner [36-38]. Since then, 
penetratin CPP derived from Antennapedia of Drosophila melanogaster in 1994 
[39, 40], and VP22 CPP derived from herpes simplex virus in 1997 [41, 42] 
were discovered.  
Recently, classification of CPPs has been suggested which can be arranged in 
three classes: protein derived CPPs, model peptides, and designed CPPs [43]. 
Protein derived CPPs generally consist of the minimal effective partial 
sequence of the parent cell-penetrating protein, and are known also as “protein 
transduction domains (PTDs)” or “membrane translocation sequences (MTSs)”. 
Model CPPs comprise of sequences that have been designed with the aim of 
producing well defined -helical structures with amphipathic properties or of 
mimicking the structures of known CPPs. Designed CPPs are generally 
chimeric peptides composed of a hydrophilic and a hydrophobic domain of 
different origin. The structures and origins of major representative CPPs are 
shown in Table 2.1.1. 
As demonstrated, CPPs from different classes have different amino acid 
sequence motifs. However, two common features can be seen, which are all 
CPPs appear to be a positive charge and amphipathicity. All known CPPs are 
net positively charged at physiological pH, and comprised of approximately 17% 
[44] to 100% (polyarginines [45, 46]) of positively charged amino acids. All 
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CPPs are amphipathic with the exception of polycationic homopolymers 
(polyarginines, polylysines and polyornithines [46-48]. Some CPPs adopt 
amphipathic character when in an -helical structure, as for instance the model 
amphipathic peptide (MAP) [49], while others have distinct hydrophobic and 
hydrophilic parts, as, for instance, the chimeric transportan CPP [50]. 
 
2.1.2 Mechanism of penetration 
The exact mechanism responsible for the uptake of CPPs and their cargos has 
not yet been fully established and has been the subject of considerable study for 
the past decades. In spite of some common features of these peptides, 
particularly their highly cationic nature and hydrophobicity, it was proposed 
that penetration mechanism is not the same for CPPs of different types. A 
number of experiments on CPP penetration in cell lines have been carried out 
under non-endocytotic and no active transport environment, where efficient 
penetration was observed at low temperatures at 4 °C and in the presence of 
many different inhibitors of endocytosis [40, 49-62]. However, recent studies 
showed that the role of endocytosis in internalization of CPP cannot be 
neglected [63, 64]. At least for some CPPs endocytosis could be an exclusive or 
alternative mechanism of internalization. It was shown that the internalization 
of penetratin peptides into the live cells is related to endocytotic processes [65] 
and that Tat derived CPPs do not enter live cells at low temperature [60] and are 
not internalized into liposomes [66]. Recently it was suggested that Tat derived  
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CPPs enter cells primarily by lipid raft-mediated macropinocytosis that is 
stimulated by cell-surface binding of Tat derived CPPs, which is an another 
form of endocytosis [68, 69].  
On the other hand, an inverted micelle mechanism was suggested for 
penetratin and Tat, in which positively charged peptides interact with negatively 
charged phospholipids to change part of the membrane into an inverted micelle 
structure that can open on either the intracellular or the extracellular side of the 
membrane [40, 64]. The cell-penetrating peptide that has an -helical structure, 
for instance MAP and, partly, transportan [70] , could be associated with pore 
formation when in contact with membrane [71, 72].  
Based on the known processes that occur during internalization, CPPs were 
classified based on their mechanisms of entry (Table 2.1.2) and a hypothetical 
lipid binding of CPPs as function of their amphipathic property and lipid 
headgroup charge was constructed (Fig. 2.1.2) [73]. As can be seen in the figure, 
internalization of CPP varies depending on their classification. The first step of 
internalization is the interaction of CPP with the cell surface. Primary 
amphipathic CPPs (paCPPs) penetrate into membranes of high and low anionic 
lipid content and induce membrane leakage. Secondary amphipathic CPPs 
(saCPPs) undergo structural change and then membrane insertion occurs. In 
contrast, no headgroup binding happens for non-amphipathic CPPs (naCPPs), 
thus no insertion but transmembrane electrical field enables the internalization 
of CPPs. It has been shown that cationic CPPs (naCPP) bind electrostatically to 
the exposed negative-charged lipid bilayer of cell membrane, which stimulates 
the macropinocytic uptake of CPPs and its cargos into macropinosomes and 
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endosomal escape into cytoplasm. The endosomal escape process is likely to be 
dependent on the pH drop in endosomes and along with other factors, which 
perturbs the endosomal membrane, thus release of CPPs and its cargo into 
cytoplasm. To date, a number of studies are now emphasizing the role of 
endocytosis [60, 74, 75], and in particular macropinocytosis [68, 76, 77], direct 
penetration [78, 79], and inverted micelle [80-82].  
 
2.1.3 Penetration of CPPs in vitro and in vivo 
The transport of CPPs across membranes has been studied in vitro cells and 
in tissues in vivo. Various mammalian cells have been used, including primary 
cells and cell lines. CPPs successfully penetrated in primary cells from brain 
and spinal cord of rat [40], aorta of calf [83], endothelium of umbilical vein 
from porcine and human [49], and in osteoclasts [84]. But mostly, cell lines 
have been used. 
For penetration to occur, no special cell cultivating procedures are needed 
with cell lines. Cells are usually grown to a certain % of confluence in dishes, 
wells, or -well plates and then can be incubated with CPP containing solution, 
which in most cases is cell culture medium. When the penetration of CPP is 
monitored directly by confocal microscopy or other imaging techniques, the 
cells are usually fixed by formaldehyde or paraformaldehyde, both of which are 
milder fixation agents than acetone, and methanol [85, 86]. It has been argued 
recently that even mild fixation can affect the internalization of some CPPs and 
artifacts may occur [60]. However, with or without the fixation process, it still 
12 
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Figure 2.1.2 (a) Schematic view of the lipid binding of CPPs as function of their 
amphipathic property and lipid headgroup charge [73]. (b) Mechanisms of 
penetration across the plasma membrane [87].  
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enabled Tat and transportan to penetrate into various cell lines (Bowes, Jurkat, 
HeLa, Caco-2) [50, 55, 57, 58, 60, 62]. 
Some penetration experiments have been performed in vivo in whole 
organisms and a small number of experiments ex vivo in isolated tissue. Ex vivo 
tissue experiments were performed mainly in isolated blood vessels. Most in 
vivo experiments were carried out with penetratin and Tat. Besides the blood 
vessel cells, penetratin was successfully used in vivo to enter peritoneally and to 
reach brain and spinal cord cells [88]. In some cases, it also by passed the 
blood–brain barrier [89-91]. Tat was used in vivo to deliver active cargo enzyme 
in cells from all tissues of mouse [92]. 
 
2.1.4 Penetration of CPPs with cargos 
The CPPs encompass ability to penetrate rapidly into living mammalian cells, 
and hence, are used to deliver various functional cargo molecules (Figure 2.1.4). 
The main applicative potential is the possibility of attaching biologically active 
cargos and delivering it into cells through penetration. Cargos can be attached 
in many ways; the most common link between the CPP and cargos is usually a 
covalent bond. When the cargos are either a peptide or protein, CPP-cargos are 
most often synthesized or expressed as fusion protein [93-95]. Or alternatively, 
a suitable amino acid as a linker or molecule as a spacer can be used. To couple 
cargos to CPPs such as transportan, the thiol group of cysteine can be used [50, 
89]. The thiol group of cysteine gets reduced in the reductive environment, thus 









CPPs and cargos, resulting in the release of cargos. Cargos can also be attached 
to CPPs by non-covalent bonds, such as biotin-conjugated CPPs to avidins [56].  
A large number of cargos have been effectively delivered into cells using CPPs, 
such as proteins [97-100], small molecules [46, 101, 102], nucleic acids [103-
105], antibodies [106, 107], and nanoparticles [108-111]. Unlike conventional 
methods, the delivery of cargo molecules using CPPs did not appear to vary by 
different cell types and efficiently delivered into cells by almost 100% [112]. 
The penetration was also accomplished within a relatively short period of time 
(less than 10 min). 
 
2.1.5 Toxicity of CPPs 
  To be used as vehicles for drug delivery, the toxicity of CPPs must be kept at 
a minimum. The in vitro toxicity of CPPs has been more frequently 
characterized than in vivo studies. For in vitro toxicity, toxic effects on 
membranes of cells and organelles, and toxic effects resulting from the specific 
interaction of CPPs with cell components have been observed. It has been 
noticed that CPPs from the class of model peptides, such as MAP, and some 
designed CPPs, such as transportan, resemble in structure the antimicrobial lytic 
peptides that kill microbial cells by disrupting their cell membranes [113, 114]. 
For concentrations over 1 M of MAP, it exerted strong toxic effects on various 
cell lines [49, 83] by the trypan blue exclusion [115], MTT [116], and 
fluorescein leakage [83] tests. Lower toxicity was observed for transportan, 
which showed toxicity from 5 M concentration, by the glucose leakage test in 
17 
 
BMC cells [117]. Penetratin is known to cause little disruption to membranes 
[117], whereas Tat appears to cause no disruption to cell membranes [51, 117]. 
Because most CPPs have net positive charge, binding to negative charge such 
as polyanions is presumed. This was confirmed with penetratin, which 
interacted with heparin, nucleic acids, and polysialic acid [118, 119]. It may be 
possible that the interaction is important for internalization but whether it is the 
cause of side effects in vivo is not known. Various toxic effects have been 
observed for other CPPs. Transportan is derived from galanin and mastoparan 
and thus encompasses some properties of both peptides. It inhibits binding of 
galanin to galanin type-1 receptor and changes the activities of heterotrimeric 
G-proteins [50]. It was shown that transportan inhibs GTPase activity with Gs. 
Although this was not observed with other types of G-proteins, this could be a 
serious problem to use transportan as a drug delivery vehicle. It must be noticed 
that the inhibition of GTPase occurs at 10 times higher concentrations than 
those used in delivery experiments. Nevertheless, the problem was overcome by 
truncating transportan, resulting in transportan-10 which has no effect on G-
proteins [52]. Tat-peptide is derived from HIV transcription factor Tat protein. 
As well as activating gene expression and replication, it is also involved in a 
number of processes including apoptosis [120, 121] and angiogenesis [122]. 
Some of these effects can be produced also with Tat derived CPPs [123]. No 
toxicity and undesirable side effects have been detected in most in vivo 
applications of CPPs [46, 89, 92]. However, when 10 g or more of penetratin 
was applied in rat by intrastriatal injection, neurotoxic cell death and 
recruitment of inflammatory cells in brain was detected; an effect which was 
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much decreased at a dose of 1 g [90]. 
The protein delivery was initially achieved by conjugation with Antp into 
various cells, including neurons [124]. Antp-fusion proteins are easily delivered 
for proteins with a size smaller than 100 amino acid residues; however 
cytotoxicity was a concern, as penetratin showed toxicity in the brain. In the 
case of trans-activating transcriptional activator (TAT) derived from HIV-1, it is 
the most intensely studied and widely used cell-penetrating peptide till date. In 
the first exon of HIV-1 TAT, a region coding from 48-60 amino acid residues 
was found to be the domain responsible for cell penetration and nuclear 
localization [116, 123, 125]. Like penetratin, TAT has been used to deliver 
functional proteins of large size into the cells and in vivo mice for the treatment 
of cancer, inflammation and other diseases [81, 126-133]. However, it should be 
noted that efficiency of penetration CPPs depend on the size and type of cargo 
being delivered. This is most noticeably demonstrated by difficulties in 
delivering large and anionic cargos, such as macromolecules and siRNAs.  
Intracellular delivery by CPPs has shown enormous potentials to deliver a 
wide range of functional molecules, such as nucleic acids, nanoparticles, and 
drugs both in vitro and in vivo [134-136]. Although several CPPs have been 
identified, it remains important to find new peptides that are efficient vehicles 
for the delivery of cargos, and with low toxicity because some have toxic 
effects on membranes of cells and organelles, including toxic effects resulting 
from the specific interaction of CPPs with cell components [35]. Moreover, lack 
of cell- and tissue-specific targeting makes CPPs difficult to be applicable in 
vivo delivery. Despite these problems, CPPs offer an easy alternative for 
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intracellular delivery of molecules in vitro and in vivo with more economical 
viability. 
 
2.1.6 Detecting internalization of CPPs 
CPPs are peptides, hence cannot usually be observed directly and must be 
either labelled or attached to cargos in which we can detect for detection of the 
small amounts that are internalized in cells. Labelled CPPs or cargos can be 
detected by fluorescence emission, fluorescence quenching, radioactivity, 
specific labelling with dyes or by enzymatic activity of the cargo. Some 
detection methods are very convenient for visualizing CPPs internalized in cells 
but the drawback is that it does not have a rapid response time for kinetic 
studies, such as visualization of internalized biotinylated transportan by labelled 
streptavidin, using confocal microscopy [50]. That is why in most cases, the 
internalization kinetic studies are performed by the CPP itself or the cargo 
molecules in CPP-cargo molecules that have been labelled by fluorophores or 
radioactive isotopes. 
Radioactively labelled cargo molecules can be used for the detection. The 
main advantage of this method is that the delivery of a cargo molecule into cells 
can be traced directly and that there may be a large variety of commercially 
available labelled compounds for use as cargo, such as commercially available 
radiolabelled antineoplastic agent, 
14
C-doxorubicin that is coupled to penetratin 
[91]. The highly sensitive and directly traceable by using radioactively labelled 
CPP or CPP-cargo construct is the main advantage of this method over others. 
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However, the disadvantage is that it requires separating the internalized cell 
fraction of the labelled compound from the bulk that remains in the incubation 
solution. Thus this method is improper and not suitable for kinetic experiments 
that require continuous monitoring of the amount of cell-internalized CPPs or 
CPP-cargo molecules.  
Fluorophores, such as fluorescein and fluorescein derivatives are frequently 
used for the detection [83, 91, 137]. After incubating cells with labelled CPPs, 
the medium is removed and the concentration of labelled CPPs inside the cells 
determined directly [138], by fluorescence flow cytometry [53], or internalized 
CPPs from cell lysate can be detected using HPLC [49].  
CPP uptake can be monitored in real time by using confocal laser scanning 
microscopy (CLSM) [125]. Attached cells are incubated with fluorescently 
labelled peptide and the time course analysis of the fluorescence inside and 
outside the cells is monitored.  
The fluorescence-based methods have a drawback in that sensitivity is lower 
than the radioactivity-based methods. The detection limit of fluorescence 
methods is close to the concentrations where some CPPs, such as MAP and 
transportan can disturb membranes [117]. For these CPPs, internalization at 
lower concentrations ( 0.1 M) would be much advised. This can be easily 


























Chapter 3. Experimental procedures 
3.1 Construction of plasmid 
Total RNA was isolated from Bombyx mori silkworm at the fifth-instar larval 
stage using RNeasy (Qiagen, Valencia, CA, USA), and 30Kc19 cDNA was 
obtained by RT-PCR. The 30Kc19 gene was amplified using PCR, and the DNA 
fragment was inserted into the pET-23a expression vector (Novagen, Madison, 
WI, USA) with a T7 tag at the N-terminus and a 6-His tag at the C-terminus. 
The GST-30Kc19 ORFs were cloned from the pGEX-4T-1 vector (GE 
Healthcare, Uppsala, Sweden) into the N-terminal of 30Kc19 in the pET-23a 
vector. The GST-30Kc19 fusion protein contained two amino acids (Glu and 
Phe) derived from the EcoRI sequence (GAATTC) between GST and 30Kc19. 
Point mutation of pET-23a/30Kc19 was requested and performed by 
Enzynomics and pET-23a/30Kc19 C57A and pET-23a/30Kc19 C76A were 
constructed. For GFP-30Kc19, ORFs of GFP were cloned from pCMV-AC-
GFP vector (Origene, Rockville, MD, USA) to N-terminal of 30Kc19 in pET-
23a vector. The GFP-30Kc19 contained two amino acids (Glu, Phe) derived 
from the EcoRI sequence (GAATTC) between GFP and 30Kc19. Truncated 
forms of 30Kc19; 30Kc191-120 and 30Kc19121-239 were also constructed. For 
GFP-30Kc19, ORFs of GFP were cloned from pCMV-AC-GFP vector (Origene, 
Rockville, MD, USA) to N-terminal of 30Kc19 in pET-23a vector. The GFP-
30Kc19 contained two amino acids (Glu, Phe) derived from the EcoRI 
sequence (GAATTC) between GFP and 30Kc19. GFP-Pep-c19; 30Kc1942-57 
sequence at the C-terminus of GFP was constructed to pET-23a vector.  
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3.2 Production and purification of proteins and peptides  
 The constructed vectors were transformed into E. coli BL21 (DE3, Novagen) 
and cells were grown in LB-ampicillin medium at 37°C. Isopropyl 1-thio--D-
galactopyranoside (IPTG, 1 mM) was used for induction. E. coli were then 
further incubated at 37°C for the production of protein, except for GFP-30Kc19, 
for which 30°C was selected as the induction temperature. After centrifugation, 
the cells were harvested and disrupted by sonication. Following cell lysis, all 
recombinant proteins except GST-fusion protein were purified from the 
supernatant using a HisTrap HP column (GE Healthcare), dialyzed against 20 
mM Tris-HCl buffer (pH 8.0) using a HiTrap Desalting column (GE Healthcare) 
with purity > 90% (data not shown), and stored at 70°C until use. For the 
GST-fusion protein, the purified protein was dialyzed against PBS (pH 7.4) and 
300 mM NaCl and stored at 70°C until use. The quantitative analysis of 
proteins was performed using a Micro BCA kit (Thermo Fisher Scientific Inc., 
Rockford, IL, USA). N-terminal FITC-linked CPP candidates and Pep-c19 with 
purity of 90% were ordered from Peptron (Daejeon, Korea), and were diluted 
and stored at −70 °C until use. 11R and Pep-c19 peptides with purity of 90% 
were ordered from Peptron (Daejeon, Korea), and were diluted and stored at 
−70 °C until use. 
 
3.3 Reducing SDS-PAGE, non-reducing SDS-PAGE, and 
native PAGE 
 All reducing SDS-PAGE, non-reducing SDS-PAGE, and native PAGE were 
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conducted using 12% polyacrylamide gels unless otherwise indicated. For the 
reducing condition, samples were mixed with reducing sample buffer 
containing SDS and -mercaptoethanol (BME) (pH 6.8), and for non-reducing 
condition, samples were mixed with non-reducing sample buffer without BME. 
15 min pre-incubation of 30Kc19 proteins with SDS, detergents, and materials 
was performed prior to loading. The reducing condition samples with the 
reducing buffer were denatured by boiling. For the native condition, samples 
were mixed with native sample buffer without any denaturing reagent. After 
electrophoresis, each sample was separated according to size (reducing or non-
reducing) or pattern (native). The polyacrylamide gel was immersed in 
Coomassie blue staining solution and then immersed in destaining solution for 
analysis. 
A 42 kDa and 67 kDa sized ovalbumin and BSA (Sigma, St. Louis, MO, 
USA) were used as standards for the molecular weight assay of the recombinant 
30Kc19 protein. SDS (Sigma) was dissolved and diluted with deionized water 
(DW) according to the appropriate concentration for the molecular weight assay. 
CTAB, Triton X-100 and CHAPS detergents (all from Sigma) were dissolved in 
DW and stored in frozen aliquots until use. Dextran sulfate sodium salt (Fluka) 
was dissolved in DW and used in the experiment. L--Phosphatidyl choline 
(Sigma) was used as the phospholipid. It was dissolved in chloroform and 
stored at 20°C until use. Prior to the experiment, the chloroform was removed 
with nitrogen gas and diluted with DW. Five controlled cycles of freeze-




3.4 Cell culture 
 HEK 293, HeLa, HEK 293-EGFP stable cell line cells were maintained in a 
humidified atmosphere of 5% CO2 at 37 °C in DMEM (Gibco, Invitrogen, 
Carlsbad, CA, USA), supplemented with 10% (w/v) fetal bovine serum (FBS, 
Gibco) and 1% (v/v) penicillin streptomycin (PS, Gibco). For the 4 °C 
experiment, cells were pre-incubated at 4 °C for 1 h before proteins were added.  
 
3.5 Immunoblot analysis 
HEK 293 cells were maintained in a humidified atmosphere of 5% CO2 at 
37°C in DMEM supplemented with 10% (w/v) fetal bovine serum (FBS, Gibco, 
Grand Island, NY, USA) and 1% (v/v) penicillin streptomycin (PS, Gibco). 
Protein was added to the culture medium and incubated for 6 h at 37°C in a 
humidified atmosphere of 5% CO2. After the incubation, cells were washed 
with PBS three times, treated with trypsin-EDTA (Sigma), then washed three 
times with PBS for strict distinction between intracellular and membrane-bound 
proteins. Cells were treated with trypsin-EDTA to distinguish between 
intracellular and membrane-bound proteins (Sigma). The collected cells were 
washed three times in PBS. Cell extracts were collected with RIPA buffer (50 
mM Tris-HCl (pH 7.4), 150 mM NaCl, 1% Triton X-100, 0.1% SDS, protease 
inhibitor cocktail) at 4 °C for 1 h followed by centrifugation. Each cell extract 
containing an equal amount of protein was resolved by PAGE and examined by 
immunoblot analysis. Anti-30Kc19 rabbit antibody was prepared using the 
following procedure. 30Kc19 was first purified from silkworm hemolymph 
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using a two-step chromatography purification method (size exclusion and ion 
exchange). Anti-30Kc19 polyclonal antibody was produced by immunizing a 
rabbit with the purified 30Kc19 protein, which was subsequently purified by 
Protein G chromatography (AbFrontier, Seoul, Korea). 30Kc19 was detected 
using this anti-30Kc19 antibody. Other primary antibodies, Anti- tubulin 
mouse monoclonal antibody, anti-EGFP rabbit polyclonal antibodies, and anti-
His tag mouse monoclonal antibody were used (all from Santa Cruz 
Biotechnology, Santa Cruz, CA, USA). For the secondary antibody, following 
antibodies were used; HRP-conjugated antibody and Alexa 488-conjugated 
antibody (Invitrogen, Carlsbad, CA, USA). 
 
3.6 Quantitative internalization analysis 
Internalization of FITC-linked Pep-c19 and GFP-Pep-c19 protein was 
measured by fluorescence intensity using a microplate reader (Tecan 
GENiosPro, Tecan, Durham, NC, USA). HeLa cells were seeded on 96-well 
plate (Nunc Lab-Tek, Thermo Scientific) and incubated overnight. FITC-linked 
peptides or protein were added to the culture medium and were incubated in 
37 °C in humidified atmosphere of 5% CO2. Unless indicated otherwise, after 
incubation, cells were washed vigorously three times with PBS to minimize the 
possible presence of membrane-bound peptides and fluorescence was measured 
with excitation at 485 nm (20 nm bandwidth) and emission at 535 nm (25 nm 
bandwidth) with a gain of 60 or excitation at 535 nm (25 nm bandwidth) and 
emission at 612 nm (10 nm bandwidth) with a gain of 60. If indicated, cells 
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were washed vigorously with PBS three times and treated with trypsin-EDTA 
for removal of membrane-bound proteins, and then fluorescence of cell lysate 
was measured. 
 
3.7 GST pull-down assay 
Purified GST-tagged proteins were prebound to resin by incubating the 
proteins with GST-bind resin for 2 h at 4 °C in PBS (pH 7.4), 300 mM NaCl, 
and a protease inhibitor mixture. The prebound resin was washed three times 
with the same buffer solution. Then, samples were analyzed by immunoblotting 
with the anti-30Kc19 rabbit antibody, followed by an HRP-conjugated anti-
rabbit antibody. 
 
3.8 Construction of HEK 293 stable cell-line expressing 
EGFP 
HEK 293 stable cell line expressing EGFP was constructed by selection 
using G-418. Transfection was performed 3 days after plating using the 
Lipofectamine 2000 (Invitrogen) according to the manufacturer’s instructions. 
HEK 293 cell was transfected with pEGFP-N1 and 1 day after transfection, the 
cells were transferred into media containing G-418 (1 mg/ml) and continuously 
cultured for 2 weeks. Only EGFP expressing colonies were selectively 





3.9 Formation of CPP/siRNA complex 
Synthetic siRNAs for EGFP siRNA sequence used: EGFP sense strand: 
Thiol-ACUACCAGCAGAACACCCC (dTdT), and EGFP antisense strand: 
(dTdT) UGAUGGUCGUCUUGUGGGG-Cy3, all purchased from Bioneer Co., 
Korea with routine process protocol set up by the company.  
The prepared siRNAs were mixed with CPPs (11R or Pep-c19) in DMEM 
and incubated for 15 min at room temperature for the formation of CPP/siRNA 
complexes. 
 
3.10 Gel shift/retardation assay for CPP/siRNA complex 
The complex formation was monitored by 2% (w/v) agarose gel in TAE 
buffer electrophoresis using molecular markers. Following electrophoresis, the 
gels were stained with 0.5 mg/ml ethidium bromide for 20 min and analyzed on 
a UV illuminator to identify the locations of siRNA.  
 
3.11 Cell viability assay 
To assess cytotoxicity of the CPP/siRNA complex, HEK 293-EGFP cells 
were seeded on a 96-well plate at 70% confluency, and CPP/siRNA in DMEM 
were added and incubated for 24 h and 72 h at 37 °C in a 5% CO2 incubator. 
Then 0.5 mg/ml MTT (3,(4,5-dimethylthiazol-2-yl)2,3-diphenyltetrazolium) 
was added to the media and incubated for 2 h. The formazan crystals that 
developed were solubilized with dimethyl sulfoxide (SigmaAldrich), and 
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absorbance was measured at 560 nm using the ELISA reader. 
 
3.12 Immunocytochemistry and live cell analysis 
 For immunocytochemistry, cell penetration of the protein was visualized 
using either confocal microscopy or fluorescence microscopy. HeLa cells were 
seeded on 8-well chamber slides (Nunc Lab-Tek, Rochester, NY, USA) and 
incubated overnight. Protein was added to the culture medium then HeLa cells 
were incubated for 6 h at 37°C in a humidified atmosphere of 5% CO2. After 
the incubation, the cells were treated with trypsin-EDTA (Sigma) and washed 
three times with PBS, fixed in 4% paraformaldehyde for 20 min, and incubated 
for 10 min with 0.25% Triton X-100 in PBS for permeabilization. The fixed 
cells were blocked with 3% BSA in 0.1% PBS-T for 1 h and then incubated 
with anti-30Kc19 polyclonal rabbit antibody (Ab Frontier), anti-T7 tag rabbit 
antibody (Abcam, Cambridge, UK), or anti-His tag mouse monoclonal antibody 
(Santa Cruz). Then, either Rhodopsin-conjugated anti-rabbit antibody (Jackson 
ImmunoResearch, West Grove, PA, USA) or Alexa Fluor 488-conjugated anti-
rabbit antibody (Invitrogen) was used for the secondary antibody. Nuclei of 
cells were stained with Hoechst 33342 for 10 min. For confocal microscopy, a 
confocal laser microscope (EZ-C1, Nikon, Tokyo, Japan) was used to observe 
intracellular fluorescence, and images were taken using the manufacturer’s 
software (Nikon).  
For live cell analysis, cell penetration was visualized using confocal laser 
microscopy (EZ-C1, Nikon, Japan). HeLa cells were seeded on 8-well chamber 
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slide (Nunc Lab-Tek, Thermo Scientific) and were incubated overnight. FITC-
linked peptide or protein was added to the culture medium and was incubated 
for 4 h at 37 °C in a humidified atmosphere of 5% CO2. Nuclei of cells were 
then stained with Hoechst 33342 for 10 min. Cells were washed vigorously 
with PBS three times to minimize the possible presence of membrane-bound 
peptides and then live cell intracellular fluorescence images were taken by the 
manufacture’s software (Nikon, Japan). 
 
3.13 Inhibitors of endocytosis 
When cell-penetrating efficiency was performed in the presence of 
cytochalasin B (25 M), sucrose (100 nM), or nystatin (25 g/ml) (all 
purchased from Sigma-Aldrich), cells were preincubated with these inhibitors 
of endocytosis for 1 h prior to supplementation of 30Kc19 protein or Pep-c19 to 
culture medium. Incubation was performed for 6 h, after which cells were 
extensively washed analyzed by immunocytochemistry method as mentioned 
previously using spectrofluorometer in order to determine the intracellular 
penetration efficiency. 
 
3.14 In vivo penetration of Pep-c19 
To investigate the in vivo penetration of Pep-c19, GFP-30Kc19 and GFP-
Pep-c19 proteins were each dissolved in PBS and intraperitoneally injected to 
5-week-old female ICR mice with an average weight of about 25 g (3.5 
mol/kg). Following 12 h incubation time, mice were euthanized and organs 
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were collected. Then, the organs were frozen with optimal cutting temperature 
(OCT, Miles Laboratories, Elkhart, IN, USA) compound and tissues were 
sectioned at a thickness of 10 m using microtome-cryostat (Microm, Walldorf, 
Germany) and were stored at −70 °C until further analysis for confocal 
microscopy. 
 
3.15 In vivo toxicity analysis 
To investigate the in vivo toxicity of Pep-c19, serum biological parameters 
were determined. 30Kc19 protein and Pep-c19 were dissolved in PBS and were 
intraperitoneally injected to 5-week-old female ICR mice with an average 
weight of about 25 g (0.2 mol/kg or 2 mol/kg). Mice were euthanized after 
14 days, and blood samples were collected by heart-puncture method, and were 
maintained in serum separating tube (SST) at room temperature for 30 min. 
Following centrifugation for 10 min at 300  g to obtain serum, samples were 
analyzed. As a parameter of kidney function, blood urea nitrogen (BUN) and 
creatinine levels were determined. For liver function, serum aspartate 
aminotransferase (AST) and alanine aminotransferase (ALT) activities were 
determined. The blood samples were delivered to Neodin Medical Institute 
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Chapter 4. Dimerization of the 30Kc19 protein in the 
presence of amphiphilic moieties and importance of Cys-57 
during cell penetration  
4.1 Introduction 
As mentioned previously, although the biological functions of the 30K 
proteins in silkworms have not been fully determined, several studies have 
recently examined their functional properties for 30Kc6 and 30Kc19 [6, 7]. In 
previous studies, it was demonstrated that gene expression or addition of 
recombinant 30K proteins to culture medium produced from Escherichia coli 
(E. coli) exhibited anti-apoptotic effects in various cells [8-20]. 30K proteins 
also enhanced productions of recombinant erythropoietin, interferon-, and 
monoclonal antibody, as well as increasing glycosylation, cell growth, and 
viability in various cells, and also had enzyme-stabilizing effects [21-28].  
Recently, the recombinant 30Kc19 protein, originating from silkworm 
hemolymph of Bombyx mori has attracted attention due to its cell-penetrating 
property and use in a protein delivery system [139]. 30Kc19 protein, is 
comprised of 239 amino acids in total, has all- helix in N-terminal domain and 
all- sheet in C-terminal domain (Figure 4.1) [140, 141]. Therefore, 30Kc19 
protein is a very unique multi-functional protein, and can be applied for the 
delivery of therapeutic proteins, including enzymes, as it can penetrate cell 
membrane as well as stabilizing cargo proteins. It is necessary to understand the 
molecular mechanism of cell penetration for the practical use of the 30Kc19  
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Figure 4.1 Structure of the 30Kc19 protein. 30Kc19 protein, comprised of 239 
amino acids in total, has all- helix in N-terminal domain and all- sheet in C-




protein. However, the exact mechanism of penetration to animal cells has not 
been fully determined and this observation of penetration across cell membrane 
has raised questions concerning the interaction of the protein-lipid bilayer. 
Herein, a dimerization propensity of the 30Kc19 protein in the presence of 
either SDS or phospholipids is reported. Then, investigated how the cell-
penetrating 30Kc19 protein is related with phospholipids, the main cell 
membrane components, and elucidated the mechanism of entry of the 30Kc19 
protein into animal cells for use in protein delivery system.  
 
4.2 Cell-penetrating property of the 30Kc19 protein 
The 30Kc19 protein has recently shown a cell-penetrating property in various 
types of cells when supplemented to culture medium, and was found to be the 
first cell-penetrating protein in insect hemolymph that exhibited a cell-
penetration property both in vitro and in vivo [139]. In this study, I investigated 
the cell-penetrating property and the intracellular penetration mechanism of the 
30Kc19 protein. First, 30Kc19 protein was added to culture medium and 
immunocytochemistry analysis showed that 30Kc19 was able to penetrate cells 
from rhodamine red color (Figure 4.2). 30Kc19 protein was localized in the 
cytoplasm of the cell and was not able to penetrate the nucleus. 
 





Figure 4.2 Cell-penetrating property of the 30Kc19 protein. HeLa cells were 
supplemented with the 30Kc19 protein in culture medium for 6 h. The cell-
penetrating ability of the 30Kc19 protein was analyzed by 
immunocytochemistry, which showed internalization of 30Kc19 protein. The 
internalized protein was visualized by Rhodopsin-conjugated anti-rabbit 
antibody (red), and nuclei were visualized with Hoechst 33342 (blue). 
Supplementing the cell culture medium with the protein was conducted in a 
quantity of 0.4 mg/ml. 
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Recently, a dimerization propensity of the 30Kc19 protein was seen during 
characterization assay using PAGE analysis, and believed its relevance with cell 
penetration. Previously, the 30Kc19 protein was run on PAGE under reducing 
and non-reducing conditions and observed the dimerization propensity. Under 
the reducing condition, a monomer and a faint dimer band were seen. In 
contrast, not only a 30 kDa sized monomer protein was detected under a non-
reducing condition but also a clear 60 kDa dimer sized protein was detected. 
These results demonstrated that the properties of the 30Kc19 protein are 
similar to other peptides under reducing and non-reducing conditions, dimer 
was considered to be due to the non-reducing environment in the presence of 
SDS [81, 142]. To confirm whether this was the case, 30Kc19 was pre-treated 
with different concentrations of SDS for 10 min and was then loaded on native 
PAGE. A monomer band was detected when no SDS was mixed with the 
protein. However, both a monomer and dimer were detected when the SDS 
concentration was increased to 0.1% (Figure 4.3(a)). A shift from the monomer 
to the dimer was detected in 0.1% SDS, and almost all monomers shifted to the 
dimer at 0.5% SDS. Therefore, 30Kc19 originally existed as a monomer and 
dimerized in the presence of SDS. Additional experiments were carried out to 
verify this for other well-known standard proteins such as ovalbumin and BSA. 
Ovalbumin and BSA were loaded on native PAGE but showed no significant 
difference in pattern as the concentration of SDS increased when compared 
with that of 30Kc19 (Figure 4.3(b)). This result shows that there was an 
increase in the size of 30Kc19, indicating dimerization of the protein. 30Kc19 




Figure 4.3 Monomer and dimer forms of 30Kc19. (a) Native PAGE result of 
the 30Kc19 protein pre-treated with different SDS concentrations. (b) Native 
PAGE result of the ovalbumin, 30Kc19, and BSA proteins, each pre-treated 




4.4 Dimerization of the 30Kc19 protein is promoted by 
phospholipid 
Dimerization propensity was seen for 30Kc19 when SDS was mixed with the 
protein. It was unclear whether this occurred because SDS is a surfactant. SDS 
is an anionic (negative) detergent; hence, cationic, non-ionic, and zwitterionic 
detergents were selected and tested for dimerization [143]. When the cationic 
surfactant CTAB was mixed with the 30Kc19 protein, no dimerization was 
observed (Figure 4.4(a)). In fact, because CTAB is a positively charged 
detergent, the 30Kc19-CTAB mixture did not progress on PAGE. Triton X-100 
and CHAPS, which are non-ionic and zwitterionic surfactants, respectively, 
resulted in no dimerization of 30Kc19, indicating that dimerization of 30Kc19 
is not just dependent on the surfactant nature of SDS and that it could be due to 
the anionic property of SDS. We hypothesized that dimerization may have been 
caused by the negative SDS charge. Hence a well-known polyanionic material, 
dextran sulfate, was used in various concentrations to determine the reason for 
the change in the 30Kc19 pattern. However, when dextran sulfate was added, 
no difference in the 30Kc19 pattern was seen (Figure 4.4(b)). We found L-α-
phosphatidylcholine, a phospholipid, which is similar in structure and 
properties to SDS, has an amphiphilic moiety and is a component of the cell 
membrane with similar structural properties to SDS (Figure 4.4(c)). When a low 
concentration of phospholipid (1 mM) was mixed with the 30Kc19 protein, no 
major tendency for a pattern shift was detected. However, as the concentration 
increased, a significant difference in the 30Kc19 protein pattern was detected 
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and dimers were seen (Figure 4.4(d)). When the lipid concentration reached 10 
mM, most of the monomeric 30Kc19 protein was in a dimer form. This result 
showed that majority of 30Kc19 shifted towards the dimer as the 30Kc19 
protein was mixed with increasing concentrations of phospholipid. This 
observation paralleled with the results shown when the 30Kc19 protein was 
mixed with SDS, a material with similar properties to phospholipid.  
 
4.5 Dimerization of 30Kc19 during cell penetration 
Previously, our group identified the cell-penetrating property of the 30Kc19 
protein when it is supplemented in culture medium [139]. Phospholipids are a 
major component of the cell membrane lipid bilayer. I hypothesized the 
possible relevance of 30Kc19 dimerization with phospholipids and the cell-
penetrating property of the 30Kc19 protein. Also the mechanism of entry of the 
30Kc19 protein into animal cells through an interaction with the cell membrane 
was elucidated. First, an immunoblot against the 30Kc19 protein incubated with 
or without SDS is shown as a reference for the pattern analysis (Figure 4.5(a), 
left). As expected, the ratio of 30Kc19 dimer to monomer increased by adding 
SDS to the solution. HEK 293 cells were incubated with 0, 0.2, and 0.4 mg/ml 
recombinant 30Kc19 protein. The cells were treated with trypsin and then 
washed multiple times to remove plasma membrane-bound protein. The cells 
were then lysed and the lysate was loaded onto native PAGE followed by an 
immunoblot against the 30Kc19 protein. Penetration of the 30Kc19 protein into 





Figure 4.4 Monomer and dimer forms of 30Kc19. (a) Native PAGE result of 
the 30Kc19 protein pre-treated with different classes of anionic (SDS), cationic 
(CTAB), non-ionic (T X-100), and zwitterionic (CHAPS) surfactant detergents. 
(b) Native PAGE result of the 30Kc19 protein pre-treated with negative 
material, dextran sulfate. (c) Schematic diagram showing similarity of SDS and 
phospholipids. (d) Native PAGE result of the 30Kc19 protein pre-treated with 




30Kc19 protein as the concentration was raised in the culture medium (Figure 
4.5(a), right). Interestingly, the 30Kc19 protein was found mainly as a dimer in 
the cell lysate, indicating that the 30Kc19 monomer protein in the medium 
dimerized during cell penetration or in the cytosol. Then, the dimerized form of 
the 30Kc19 protein in the cytosol using a GST pull-down assay followed by a 
reducing PAGE immunoblot was further confirmed. GST-30Kc19 was 
produced in E. coli and loaded on reducing PAGE (Figure 4.5(b)). A 60 kDa 
sized monomer GST-30Kc19 protein was detected under reducing conditions, 
and confirmed that the protein was expressed and purified successfully. Then, 
the 30Kc19 protein, the GST-30Kc19 protein, or 30Kc19 protein plus GST-
30Kc19 protein, respectively was added to HEK 293 cell culture medium. The 
cell lysates were loaded onto reducing PAGE, and confirmed that both the 
30Kc19 protein and GST-30Kc19 penetrated the cells (Figure 4.5(c)). When the 
30Kc19 protein-treated cell lysate was subjected to the GST pull-down assay, 
no 30Kc19 protein was detected, as expected, whereas the GST-30Kc19 protein 
was detected when the GST-30Kc19 protein-treated cell lysate was used. 
However, when the cell lysate treated with both the 30Kc19 protein and GST-
30Kc19 protein was subjected to the GST pull-down assay, the 30Kc19 protein 
was detected. Based on these results, it was concluded that the 30Kc19 protein 
formed a dimer with 30Kc19 of GST-30Kc19 during penetration and remained 
a dimer inside the cells (Figure 4.5(d)). Therefore, it is suggested that the 
30Kc19 protein interacted with phospholipid on the plasma membrane and 




Figure 4.5 Dimerization of 30Kc19 during cell penetration. (a) Native PAGE 
immunoblot result of the 30Kc19 protein pre-treated with SDS (left) and cell 
lysate supplemented with 30Kc19 in culture medium for 6 h (right). (b) 
Reducing SDS-PAGE result of the 30Kc19 and GST-30Kc19 fusion proteins in 
solution. (c) Reducing PAGE immunoblot result of the HEK 293 cell lysate, 
supplemented with the 30Kc19 protein only, the GST-30Kc19 protein only, or 
the 30Kc19 plus GST-30Kc19 proteins in culture medium for 6 h. (d) HEK 293 
cells were supplemented with the 30Kc19 protein only, the GST-30Kc19 
protein only, or the 30Kc19 plus the GST-30Kc19 proteins in culture medium 
for 6 h. Reducing PAGE immunoblot result of the cell lysate GST pull-down 
assay. Proteins were supplemented in the culture medium in equal molar 




4.6 Importance of 30Kc19 Cys-57 for cell penetration 
I was convinced that the 30Kc19 protein dimerizes during cell penetration 
but were unsure exactly how the 30Kc19 protein homodimerizes during 
penetration. A similar result was demonstrated with the peptide hormone 
resistin in which a disulfide-linked homodimer was converted to a monomer 
under reducing conditions and conversion of a single cysteine to alanine 
abolished the dimerization [144, 145]. The 30Kc19 protein has two cysteine 
residues, Cys-57 and Cys-76 (Figure 4.6(a)). There is high probability that one 
of these cysteines is involved in dimerization of the 30Kc19 protein. Thus, a 
point mutation in pET-23a/30Kc19 was requested and pET-23a/30Kc19 C57A 
and pET-23a/30Kc19 C76A were constructed (Enzynomics). Expression and 
purification of the 30Kc19 C57A and 30Kc19 C76A proteins were performed 
by the same method as for the 30Kc19 protein, and they were analyzed by 
reducing SDS-PAGE (Figure 4.6(b)). The result showed that both proteins were 
expressed successfully. Then, the 30Kc19 protein, the 30Kc19 C57A protein, 
and the 30Kc19 C76A protein were added in equal amounts (0.4 mg/ml) to 
culture medium containing HEK 293 cells. The cell lysates were loaded onto 
reducing PAGE, and confirmed that the 30Kc19 protein and 30Kc19 C76A 
penetrated the cells by immunoblot analysis. However, the 30Kc19 C57A 
protein-treated cell lysate showed no sign of the penetration, indicating that the 
30Kc19 protein cannot penetrate cells without Cys-57 (Figure 4.6(c)). 
Additionally, the dimerization propensity on native PAGE of 30Kc19 C57A and 
30Kc19 C76A by immunoblot analysis was checked (Figure 4.6(d)). Similar to 
45 
 
the wild-type 30Kc19 protein, 30Kc19 C57A, and 30Kc19 C76A showed no 
signs of dimerization in the absence of cell penetration (Figure 4.6(d)). 
However, when each of the protein-treated HEK 293 cell lysates was loaded 
onto native PAGE for immunoblot analysis, we observed that only the 30Kc19 
protein and 30Kc19 C76A penetrated the cells and existed as dimers inside the 
cells (Figure 4.6(d)). Immunocytochemistry of the 30Kc19 proteins was used to 
confirm penetration of 30Kc19 and 30Kc19 C76A but not 30Kc19 C57A. Note 
that 30Kc19 C57A was not detected inside the cells, but 30Kc19 C76A 
managed to penetrate the cells (Figure 4.6(e)). Thus, conversion of this cysteine 
to alanine at 57 abolished dimerization of 30Kc19, indicating that a single 
disulfide bond was necessary to connect the two 30Kc19 proteins into a 
homodimer and that 30Kc19 protein can only penetrate the cell membrane by 
dimerization. The cysteine residue at 57 is critical for cell penetration, which 
means it is involved in dimer formation between the 30Kc19 proteins. Although 
one can presume formation of multimer, this is quite unlikely because only 
monomer and dimer were shown in non-reducing PAGE analysis indicating that 
multimer is not formed. 
However, one cannot rule out the possibility that dimer was formed during 
cell lysis and PAGE steps. Although it is highly unlikely that oxidation occurred 
and dimer was formed during this step; certainty can be made by in vivo 




Figure 4.6 Importance of 30Kc19 Cys-57 for cell penetration. (a) Alignment of 
30Kc19 and mutated 30Kc19 Cys and Ala residues highlighted in bold. (b) 
Reducing SDS-PAGE result of the 30Kc19 protein, 30Kc19 C57A, and 30Kc19 
C76A. (c) Reducing PAGE immunoblot result of the HEK 293 cell lysate 
supplemented with each protein. (d) Native PAGE immunoblot result of each 
protein (left), and the HEK 293 cell lysate supplemented with each protein 
(right). Monomeric and dimeric species are indicated by arrows. (e) HeLa cells 
were supplemented with each protein. The cell penetration was analyzed by 
visualized by Alexa Fluor 488 (green), and nuclei were visualized with Hoechst 
33342 (blue). Equal molar quantity of 0.4 mg/ml and 6 h for all proteins. 
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4.7 Intracellular penetration in the presence of inhibitors 
of endocytosis 
Cells were treated with inhibitors of endocytosis; cytochalasin B, sucrose, and 
nystatin, for the disruption of microfilaments/inhibition of macropinocytosis, 
inhibition of clathrin-mediated endocytosis, and disruption of caveolar structure 
and function, respectively [102]. When cells were given a hyperosmolar 
condition by sucrose treatment, no markedly difference in the penetration 
ability of the 30Kc19 protein was seen (Figure 4.7). This showed that 30Kc19 
protein does not penetrate by clathrin-mediated endocytosis. However, 
treatment of cytochalasin B or nystatin slightly lowered the cell-penetrating 
ability of the 30Kc19 protein, which demonstrates that 30Kc19 protein 
penetrates cells by macropinocytosis and caveolin-mediated endocytosis. But 
because the level of decrease in the penetration is low when cytochalasin B or 
nystatin was treated, it may be possible that the 30Kc19 protein internalizes by 
other methods of entry. 
 
4.8 Intracellular cargo delivery using the 30Kc19 protein 
A recent study has shown that 30Kc19 protein has a cell-penetrating property 
when supplemented to the culture medium [139]. In order to examine the ability 
of 30Kc19 protein to deliver foreign proteins into the cell, a GFP was selected 
because of its cell-impermeable property and ability to give out its own green 




Figure 4.7 Intracellular penetration in the presence of inhibitors of endocytosis. 
Cells were pre-incubated for 1 h with different modulators of endocytosis; 
cytochalasin B (25 M) for the disruption of microfilaments/inhibition of 
macropinocytosis, sucrose (100 mM) for the inhibition of clathrin-mediated 
endocytosis, and nystatin (25 g/ml) for the disruption of caveolar structure and 
function. Protein was supplemented to the medium and after 6 h of incubation, 
HeLa cells were fixed with paraformaldehyde. The intracellular 30Kc19 protein 
was visualized by Alexa Fluor 488-conjugated anti-rabbit antibody fluorescence 
was measured using spectrofluorometer (ex. 485 nm/em. 535 nm). *p  0.001, 




  impermeable cargo is possible and also because of ease of assay via 
intracellular fluorescence. Thus, GFP-30Kc19 protein expressed from E. coli, 
purified, and was added to culture medium. The results showed that when the 
30Kc19 protein is fused with GFP, it was able to penetrate and deliver its cargo 
protein into cells (Figure 4.8). This means that we can utilize the 30Kc19 
protein for successful intracellular delivery of cargo proteins. Also, it 
demonstrates that in vivo delivery of cargos to tissues and organs may be 
achieved using this 30Kc19 protein as a fusion partner. Other than cargo 
proteins, it is expected that 30Kc19 protein may also intracellularly deliver cell-
impermeable cargo molecules such as oligonucleotides when conjugated to the 
30Kc19 protein.  
 
4.9 Penetration mechanism of the 30Kc19 protein 
We observed that the dimerization characteristic of the 30Kc19 protein was 
similar to a representative PTD, Antennapedia (Antp) [34]. This Antp PTD also 
exhibits a very similar pattern during interactions with SDS and cell membranes 
[40]. Dimerization of Antp also has the characteristic of penetrating inside cell 
in an energy independent manner. In addition, dimerization propensities of the 
fibroblast growth factor receptors 3 (FGFR3) transmembrane domains in 
detergents and in lipid bilayers were observed previously [146]. Like the 
30Kc19 protein, cysteine was involved in the propensity for dimerization, 
which suggests that the nature of the hydrophobic environment plays an 




Figure 4.8 Intracellular cargo delivery using the 30Kc19 protein. HeLa cells 
were supplemented with the GFP or GFP-30Kc19 fusion protein in culture 
medium for 6 h. Ability of the 30Kc19 protein to intracellularly deliver GFP 
fusion protein (GFP-30Kc19) was analyzed by immunofluorescence, which 
showed internalization of GFP-30Kc19 protein. The internalized protein was 
visualized by its own signal of GFP protein, and nuclei were visualized with 
Hoechst 33342 (blue). Supplementing the cell culture medium with the protein 





capability of the 30Kc19 protein to propensity for dimerization is thought to be 
similar manner to TM domain of FGFR3. Others reported that Penetratin (Antp) 
penetrates into cells by hydrophobic amino acids which insert into the core of 
cell membrane and cause change in the orientation of the negatively charged 
phospholipid head group [147]. To cross cell membranes efficiently is thought 




Figure 4.9 Schematic diagram of 30Kc19 protein monomer that dimerizes at 
the surface of the cell membrane and penetrates the cell as a dimer. The 
capability of the 30Kc19 protein to cross the cell membrane efficiently is 
thought to be similar to other CPP mechanism of entry into cells. The 30Kc19 
protein is arbitrarily represented as a dimer in this model. The protein recruits 
negatively charged phospholipids (black circles) at the plasma membrane. The 








Recently, the recombinant 30Kc19 protein, originating from silkworm 
hemolymph of Bombyx mori has attracted attention due to its cell-penetrating 
property and use in a protein delivery system. However, this observation of 
penetration across cell membrane has raised questions concerning the 
interaction of the protein-lipid bilayer. Here, a dimerization propensity of the 
30Kc19 protein was seen in the presence of amphiphilic moieties; SDS or 
phospholipid. Native PAGE showed that the 30Kc19 monomer formed a dimer 
when SDS or phospholipid was present. In the GST pull-down assay, 
supplementation of the 30Kc19 protein to mammalian cell culture medium 
showed dimerization and penetration; due to phospholipids at the cell 
membrane, the main components of the lipid bilayer. Mutagenesis was 
performed, and penetration was observed by 30Kc19 C76A and not 30Kc19 
C57A, which meant Cys-57 is involved in dimerization of the 30Kc19 at the 
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Chapter 5. Prediction and identification of cell-penetrating 
peptide of the 30Kc19 protein (Pep-c19) 
5.1 Introduction 
In the past two decades a new class of peptides has gained increasing 
attention. These so-called “cell-penetrating peptides” are usually less than 30 
amino acids in length, and are comprised of cationic and/or hydrophobic 
residues [34, 35]. These cell-penetrating peptides have the ability to penetrate 
rapidly into living mammalian cells, and hence, can be used to deliver various 
functional cargo molecules, such as proteins [97-100], small molecules [46, 101, 
102], nucleic acids [103-105], antibodies [106, 107], and nanoparticles [108-
111] (Figure 5.1). The exact mechanism responsible for the uptake of CPPs and 
their cargoes has not yet been fully established; however, a number of studies 
are now emphasizing the role of endocytosis [60, 74, 75], and in particular 
macropinocytosis [68, 76, 77], direct penetration [78, 79], and inverted micelle 
[80-82]. Proteins and peptides have been found to move across the cell 
membrane since the initial discovery of TAT CPP derived from HIV-1 virus in 
1988 [36, 37], penetratin CPP derived from Antennapedia of Drosophila 
melanogaster in 1994 [39, 40], and VP22 CPP derived from herpes simplex 
virus in 1997 [41, 42]. Although several CPPs have been identified, it remains 
important to find new peptides that are efficient vehicles for the delivery of 
cargos, and with low toxicity because some have toxic effects on membranes of 
cells and organelles, including toxic effects resulting from the specific 
interaction of CPPs with cell components [35]. 
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Although the biological functions of the 30K proteins in silkworms have not 
been fully determined, several studies have recently examined their functional 
properties for 30Kc6 and 30Kc19 [6, 7]. A recent study has shown that 30Kc19 
protein has a cell-penetrating property when supplemented to the culture 
medium [29]. Therefore, 30Kc19 protein is a very unique multi-functional 
protein, and can be applied for the delivery of therapeutic proteins, including 
enzymes, as it can penetrate cell membrane as well as stabilizing cargo proteins. 
However, for the practical use in delivery of cell-impermeable cargo molecules, 
it is necessary to find a cell-penetrating domain like other cell-penetrating 
proteins that can efficiently deliver cargo molecules into cells. 
Here, a cell-penetrating peptide of 30Kc19 protein (Pep-c19), originating 
from the silkworm is reported. It demonstrates how CPP candidates were 
selected, and tested for identification of a peptide domain that has a cell-
penetrating property. 
 
5.2 Presence of CPP in the 30Kc19 protein 
  30Kc19 protein, comprised of 239 amino acids in total, has all- helix in 
N-terminal domain and all- sheet in C-terminal domain as shown in Figure 
5.2(a) [140, 141]. Recently, our group has shown cell-penetrating property in 




Figure 5.1 Schematic diagram of application of cell-penetrating peptides as 





cells when supplemented to culture medium. It was found to be the first cell-
penetrating protein in insect hemolymph that exhibited a cell-penetration 
property both in vitro and in vivo [139]. In this study, the presence of CPP 
within the 30Kc19 protein was first investigated. To determine whether 
penetration of 30Kc19 is dependent on the structure of the protein itself, and to 
confirm the presence of CPP in the 30Kc19 protein, N- and C-terminal 
truncated forms of 30Kc19 protein were constructed (Figure 5.2(b)), expressed 
and purified. The soluble forms of 30Kc191-120 and 30Kc19121-239 were seen 
from the Western-blot analysis (Figure 5.2(c)). However, 30Kc191-120 was 
expressed more as soluble form and 30Kc19121-239 was expressed less as soluble 
form. This indicates that 30Kc19121-239 is mostly produced as misfolded proteins; 
inclusion bodies and refolding into bioactive forms is necessary. Hence only 
soluble forms of proteins were used. HEK 293 cell was used for Western-blot 
analysis as in previous study to compare the cell-penetrating ability of 30Kc191-
120 and 30Kc19121-239 with the 30Kc19 protein [139]. When cells were incubated 
with soluble form of N-terminal truncated 30Kc19 (30Kc191-120) at both 37 °C 
and 4 °C, 30Kc191-120 protein was found in the cell (Figure 5.2(d)). Unlike the 
30Kc191-120 protein, 30Kc19121-239 protein was not found in the cell and further 
experiments were not carried out (data not shown). This raised a question of the 
possible presence of a cell-penetrating peptide within the 30Kc19 protein. It 
was likely that the N-terminal truncated domain was responsible for the cell-







Figure. 5.2 Cell-penetrating property of 30Kc19 protein and demonstration of 
potential presence of cell-penetrating peptide in the 30Kc19 protein. Unless 
indicated otherwise, 0.2 mg/ml of proteins were used in the culture medium and 
were incubated with HEK 293 cells for 4 h. All figures are the results from 
immunoblots of whole cell lysate using the anti-30Kc19 antibody. (a) 3D 
representation structure of 30Kc19 protein using Swiss-model program. (b) 
Schematic diagram of the proteins related to this work. (c) Truncated 30Kc191-
120 and 30Kc19121-239 proteins. (d) Cell-penetrating property of truncated 
30Kc19 protein at low temperature. When the cells were incubated with 
30Kc191-120 at 4 °C as well as 37 °C, 30Kc19 protein was detected in both cases. 
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5.3 Identification of 30Kc19 CPP (Pep-c19)  
The possible location of CPP within the 30Kc19 protein was predicted. Most 
CPPs have common characteristics, in that they have relatively high positive 
charge from basic amino acids such as arginine and lysine, and also have 
relatively high hydrophobicity from hydrophobic residues [34, 35]. Also, taking 
penetratin from Antennapedia into account, evaluation was performed that 
CPPs are also likely to be found in the secondary structure of helix motif and 
surface with relatively high accessibility [149, 150]. Then the 30Kc19 sequence 
was analyzed for high frequency of basic amino acids, as well as hydrophobic 
amino acids in close proximity. Helix motif, positive surface charge, 
hydrophobicity, and relative surface accessibility were analyzed and showed 
that 30Kc1945-55 satisfied the characteristics and hence, it was selected as being 
the most probable candidate for the CPP within in the 30Kc19 protein.  
In order to examine whether this region of 30Kc19 domain encompasses CPP, 
17 peptides conjugated with FITC were synthesized (Figure 5.3(a)). We 
extended the peptide sections starting from 41 to 57 because of hydrophobic 
amino acids at 41 (Val) and 42 (Ile), and Cys at 57. We expected hydrophobic 
amino acid is an important factor because Antp43-58 sequence 
(RQIKIWFQNRRMKWKK) contains 6 hydrophobic amino (Ile, Ile, Trp, Phe, 
Met, Trp) acids in total. In addition, it was expected that cysteine may be an 
important factor because of previous report that it may be involved in the 
process of internalization via formation of dimer [142]. HeLa cell was used for 
intracellular fluorescence analysis as in previous study [139]. To narrow down 
61 
 
the search for cell-penetrating peptide, each FITC-linked peptide was added to 
culture medium and cells were later washed vigorously with PBS several times 
to remove any cell-bound peptides. Intracellular fluorescence from each peptide 
was measured using a spectrofluorometer. Out of 3 sections; 30Kc19x-55, 
30Kc19x-56, and 30Kc19x-57, each showed high fluorescence, as indicated 
(Figure 5.3(b)). However, because washes in PBS may not be sufficient to 
remove some membrane-bound peptides, 2 peptides from each section were 
selected (red arrow), and thus, 6 peptides; 30Kc1941-55, 30Kc1942-55, 30Kc1941-56, 
30Kc1942-56, 30Kc1944-57, 30Kc1945-57 were closely examined for their cell-
penetrating ability by using confocal microscopy. The results showed that 2 
peptides; 30Kc1944-57 and 30Kc1945-57, were visualized in cytoplasm and were 
able to penetrate the plasma membrane (Figure 5.3(c)). The results are similar 
to HIV-TAT and Antp [69, 151]. On the other hand, 4 peptides; 30Kc1941-55, 
30Kc1942-55, 30Kc1941-56 and 30Kc1942-56, were unable to penetrate the cell, and 
some actually formed membrane-bound aggregates (data not shown), which 
could explain the fluorescence given out in Figure 5.3(b). The formation of 
aggregates could have risen from the hydrophobic amino acids; Val-41 and Ile-
42, where the number of hydrophobic amino acids in those 4 peptides was too 
many to allow for stability and solubility in the culture medium. 30Kc1945-57 is 
shorter in length than 30Kc1944-57, and thus, 30Kc1945-57 was chosen as the CPP 
of 30Kc19 protein. Thus, 30Kc1945-57, which will be named “Pep-c19”, was 
found to be the cell-penetrating peptide from 30Kc19 protein that efficiently 




Figure 5.3 Identification of Pep-c19. (a) FITC-linked peptides were selected 
based on the computational results for the cell-penetrating ability. (b) 
Intracellular fluorescence of 30Kc19x-y CPP candidates was measured using 
spectrofluorometer (ex. 485 nm/em. 535 nm). *p  0.001, compared with the 
FITC-treated group (n = 6). Error bars represent standard deviation. (c) 
Confocal microscopy image of the cell internalization of 30Kc19x-y CPP 
candidates in living cells. In all cases, HeLa cells were incubated for 4 h with 
the same molar concentration of 30Kc19x-y peptides (10 M). The cell 
internalization of 30Kc19x-y peptides were visualized by FITC fluorescence 
(Green) and nuclei were visualized by Hoechst 33342 (Blue). x and y denote 
the amino acid number of 30Kc19 protein.  
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5.4 Intracellular penetration in the presence of inhibitors 
of endocytosis 
 It was notable that Pep-c19 successfully penetrates into cells and tissues upon 
addition to culture medium and intraperitoneal injection to mice, respectively. 
However, the mode of intracellular penetration was still unknown. Hence, 
inhibitors of endocytosis were used to find out how the Pep-c19 penetrates into 
cells. Prior to the treatment of FITC-Pep-c19 peptide, HeLa cells were treated 
with inhibitors of endocytosis; cytochalasin B, sucrose, and nystatin, for the 
disruption of microfilaments/inhibition of macropinocytosis, inhibition of 
clathrin-mediated endocytosis, and disruption of caveolar structure and function, 
respectively (Figure 5.4) [102]. Sucrose was treated to give cells a 
hyperosmolar condition, but no markedly difference in the penetration ability of 
the Pep-c19 was seen. This showed that Pep-c19 does not penetrate by clathrin-
mediated endocytosis. However, when cytochalasin B or nystatin was treated to 
cells, slightly lowered cell-penetrating ability of the Pep-c19 was seen, which 
demonstrates that it penetrates cells by macropinocytosis and caveolin-mediated 
endocytosis. Others reported that cytochalasin B reduced the cellular uptake of 
CPP by half [152], and nystatin reduced the CPP reporter -gal activity by 50% 
in various cells [153]. The mechanism of entry of Pep-c19 is similar to other 
CPPs, but Pep-c19 involves 2 uptake pathways. In our current studies, we are 
undergoing molecular mechanism study of Pep-c19 for clarification of 




Figure. 5.4 Intracellular penetration in the presence of inhibitors of endocytosis. 
HeLa cells were pre-incubated for 1 h with various endocytosis inhibitors; 
cytochalasin B (25 M) for the disruption of microfilaments/inhibition of 
macropinocytosis, sucrose (100 mM) for the inhibition of clathrin-mediated 
endocytosis, and nystatin (25 g/ml) for the disruption of caveolar structure and 
function. FITC-linked Pep-c19 peptide was supplemented to the medium and 
after 6 h of incubation, HeLa cells were vigorously washed three times with 
PBS. The intracellular FITC-Pep-c19 was measured by green fluorescence 
using spectrofluorometer (ex. 485 nm/em. 535 nm). *p  0.05, compared with 





5.5 Comparison of Pep-c19 with other cell-penetrating 
peptides 
  Well-known cell-penetrating peptides derived from protein transduction 
domains are Tat from human immunodeficiency virus-1 (HIV-1) [36, 37], 
VP22 from herpes simplex virus-1 (HSV-1) [41, 42], and Antp (also known as 
Penetratin) from Antennapedia homeodomain [39, 40]. In this research, a new 
cell-penetrating peptide was found from the third helix of Bombyx mori 
silkworm hemolymph. Pep-c19, in comparison with other CPPs in terms of the 
primary structure, Pep-c19 CPP contains less positive amino acids (3 in the 
sequence) than other CPPs (TAT has 8, VP22 has 9, Antp; has 7) (Table 5.5). 
Instead, Pep-c19 has more hydrophobic acids (6 in the sequence) than the most 
of other CPPs (TAT has 0, VP22 has 1, Antp has 6). With the secondary 
structure, Antp’s homeodomain is comprised of 60 residues and it is consisted 
of 3 alpha-helices. Third alpha-helix is responsible for penetration (Antp), 
which is similar to our Pep-c19, because it is also from the third alpha helix of 
the 30Kc19 protein. HSV-1 protein has a size that is a little bigger than the 
30Kc19 protein, 38 kDa, and VP22 is located at the very last 34 residues. These 
CPPs have been used to transduce proteins into cells and tissues and for some 
(Tat and Antp) even across blood brain barrier but efficiency various depending 
on the cargo that is attached to the CPPs [154]. Though advantages and 
disadvantages exist among the CPPs, the major advantage of Pep-c19 is that it 
is not a virus-derived cell-penetrating peptide meaning it is applicable as a 
therapeutic tool, short length, and is not toxic.   
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Table 5.5 Comparison of Pep-c19 with other cell-penetrating peptides. 
 (Red color: positive amino acid, blue color: hydrophobic amino acid) [154] 





(HIV-1 TAT); residues 48-60 
GRKKRRQRRRPPQ (13) 
Able to transduce 15 – 120 kDa proteins into cells with high 
efficiency (~100%). In vivo delivery after 4 h into various 
tissues and across BBB. 
VP22 
Herpes simplex virus-1 protein 
22 (HSV-1); residues 266-301 
DAATATRGRSAASRPTERPRA
PARSASRPRRPVD (34) 
38 kDa size with last 34 residues responsible for penetration. 






Consists of 3 alpha-helices. Third helix responsible for 
penetration; in vivo delivery into brain within 30 min. 
Nona-arginine 
(R9) 
Polyarginine RRRRRRRRR (9) 
Polyarginine peptides of 4-16 residues tested with 8 and 9 
being optimal. Able to transduce molecules into a variety of 
cells in culture. 
Pep-c19 
Bombyx mori 30Kc19 protein; 
residues 45-57 
VVNKLIRNNKMNC (13) 
28 kDa size with 13 residues in third helix responsible for 





A new CPP; VVNKLIRNNKMNC, from 30Kc19 protein was identified and 
demonstrated that 30Kc19 exhibited a cell-penetrating property due to the 
presence of a cell-penetrating peptide at 45-57. The mode of intracellular 
penetration was evaluated by the use of inhibitors of endocytosis to find out 
how the Pep-c19 penetrates into cells. Sucrose was treated to give cells a 
hyperosmolar condition, but no markedly difference in the penetration ability of 
the Pep-c19 was seen. This showed that Pep-c19 does not penetrate by clathrin-
mediated endocytosis. However, when cytochalasin B or nystatin was treated to 
cells, slightly lowered cell-penetrating ability of the Pep-c19 was seen, which 
demonstrates that it penetrates cells by macropinocytosis and caveolin-mediated 
endocytosis. The results strongly suggest that Pep-c19 has great potential for 
the efficient delivery of micro- and macromolecules including drugs and 
proteins to target tissues for therapeutic purposes. Since Pep-c19 is a cell-
penetrating peptide derived from the first cell-penetrating protein that has been 
found in insect hemolymph, anticipate that other cell-penetrating peptides will 
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Chapter 6. In vitro and in vivo protein delivery system 
using cell-penetrating peptide of the 30Kc19 protein (Pep-
c19) 
6.1 Introduction 
The transport of CPPs across membranes has been studied in vitro cells and 
in tissues in vivo. Various mammalian cells have been used, including primary 
cells and cell lines. CPPs successfully penetrated in primary cells from brain 
and spinal cord of rat [40], aorta of calf [83], endothelium of umbilical vein 
from porcine and human [49]. But in most cases, cell lines have been used. 
For penetration to occur in vitro, no special cell cultivating procedures are 
needed with cell lines. Cells are usually grown to a certain % of confluence in 
dishes, wells, or -well plates and then can be incubated with CPP containing 
solution, which in most cases is cell culture medium.  
Only a few penetration experiments have been performed in vivo in whole 
organisms and even fewer ex vivo in isolated tissue. Ex vivo tissue experiments 
were performed mainly in isolated blood vessels. Most in vivo experiments 
were carried out with penetratin and Tat. Besides the blood vessel cells, 
penetratin was successfully used in vivo to enter peritoneally and to reach brain 
and spinal cord cells [88]. In some cases, it also by passed the blood–brain 
barrier [89-91]. Tat was used in vivo to deliver active cargo enzyme in cells 
from all tissues of mouse [92]. Proper kinetic experiments are mostly obtained 
with cells from cell lines because although ex vivo and in vivo experiments 




mechanism of internalization, and particularly for demonstrating the drug 
delivery potential of CPPs, these experiments are not suitable for studies of 
kinetics of internalization because of difficulties in obtaining sufficient kinetic 
data under well-defined and reproducible experimental conditions. 
Hence, for the practical use in delivery of cell-impermeable cargo molecules, 
it is necessary to characterize CPP-conjugated cargos whether it can efficiently 
deliver cargo molecules into cells both in vitro and in vivo (Figure 6.1). 
Here, the cell-penetrating peptide of 30Kc19 protein (Pep-c19), originating 
from the silkworm is tested for cell-penetrating property. The efficiency and 
toxicity of this “Pep-c19” in comparison with its original protein, 30Kc19, both 
in vitro and in vivo are also investigated.  
 
6.2 In vitro protein delivery of protein-conjugated Pep-c19 
In order to examine the ability of Pep-c19 to deliver foreign proteins into the 
cell as well as its cell-penetrating efficiency, a GFP-Pep-c19 as well as GFP and 
GFP-30Kc19 was expressed in E. coli and purified (Figure 6.2(a)). HeLa cell 
was used for fluorescence analysis as in previous study to compare the cargo-
delivering ability of Pep-c19 with the 30Kc19 protein [139]. Each protein was 
added to culture medium of HeLa cells and the increase in intracellular GFP- 
Pep-c19 was determined to be dependent on the concentration of the protein in 
the culture medium. The efficiency of the Pep-c19 was higher than the GFP-
30Kc19, even after vigorous washing with PBS for the removal of any cell- 






Figure. 6.1 Intraperitoneal injection of Pep-c19 and organ preparation from 




GFP-Pep-c19 was dependent on the time of the protein in the culture medium, 
and the efficiency of the Pep-c19 was also higher than the GFP-30Kc19, after 
vigorous washing with PBS (Figure 6.2(c)). Then, each protein was added to 
the culture medium of HeLa cells and immunocytochemistry was performed. 
Similar to GFP-30Kc19, GFP-Pep-c19 also penetrated into the cells. Live cell 
images were taken under confocal microscope after vigorous washing with PBS 
to exempt membrane-bound proteins and possible artifacts from fixation 
process of immunocytochemistry, where cell surface-bound proteins could be 
moved into cells [155]. The confocal images indicated that GFP-Pep-c19 
successfully penetrated inside the living cells (Figure 6.2(f)). Similar to Figure 
5.3(c), it was worthwhile to notice that GFP-Pep-c19 was visualized in a 
punctate form. It was shown that internalized foreign proteins fused with the 
cell-penetrating peptide were observed as punctate forms [151, 156]. 
Quantification of the intracellular fluorescence from the cell lysate was 
performed to fully exclude the possible membrane-bound proteins. Protein-
treated cells were treated with trypsin-EDTA for removal of membrane-bound 
proteins and then fluorescence of cell lysate was measured (Figure 6.2(f)). The 
result showed that both GFP-30Kc19 and GFP-Pep-c19 proteins were located in 
the cell lysate, but more GFP-Pep-c19 was found inside the cell. These results 
demonstrated that Pep-c19 can, not only penetrates itself, but it is also able to 
deliver impermeable cargo proteins, such as GFP into the cell with higher 






Figure 6.2 Delivery of GFP into the cells by Pep-c19. (a) SDS-PAGE result of 
proteins. (b) Intracellular fluorescence in dose-dependent (4 h) and (c) time-
dependent (10 M) manner was measured using spectrofluorometer (ex. 488 
nm/em. 515 nm) (n = 6). (d) Immunocytochemistry image of the HeLa cell 
internalization of GFP-Pep-c19 using confocal microscopy. (e) Confocal 
microscopy image in living cells. The GFP-Pep-c19 was visualized by GFP 
fluorescence (Green) and nuclei were visualized by Hoechst 33342 (Blue) (4 h, 
10 M) (f) Intracellular fluorescence of GFP-Pep-c19 (10 M, 6 h) was 
measured after trypsin-EDTA for removal of membrane-bound proteins using 
spectrofluorometer (ex. 488 nm/em. 515 nm) (n = 3). Error bars represent 




6.3 In vivo protein delivery of protein-conjugated Pep-c19 
Previously, CPPs have been used to successfully deliver cell-impermeable 
cargos such as proteins [97-100], small molecules [46, 101, 102], nucleic acids 
[103-105], antibodies [106, 107], and nanoparticles [108-111] either in vitro and 
in vivo. To investigate in vivo penetration and efficiency in comparison with the 
whole 30Kc19 protein, we intraperitoneally injected each protein to 5-week-old 
ICR mice, and the organs, including brain, heart, lung, kidney, and liver, were 
isolated 12 h after injection [92, 157, 158]. In order to avoid an artifact and to 
address the potential issue caused by fixation process from 
immunohistochemistry, fluorescence images were taken without the fixation 
process, and thus, the penetration of GFP-Pep-c19 into tissues was analyzed by 
the fluorescence from the GFP protein. No fluorescence was detected for the 
native GFP in tissues (Figure 6.3, top panel). Fluorescence was detected in all 
the tissues except the brain (Figure 6.3 (a), (b), (c), (d)), isolated from the 
mouse that were injected with GFP-30Kc19 and GFP-Pep-c19, although the 
fluorescence intensities varied among tissues (Figure 6.3, middle panel). For 
GFP-Pep-c19, we observed that fluorescence intensity was much higher than 
that from GFP-30Kc19 in tissues (Figure 6.3, bottom panel). This indicates that 
Pep-c19 penetrated and delivered cargo into various tissues across the blood 
vessel barriers with a high efficiency. No fluorescence was detected for all 
groups in the brain tissue, indicating the both the 30Kc19 and Pep-c19 are 
unable to penetrate and deliver cargos across the blood brain barrier (BBB) 




6.4 Toxicity test for the long-term administration of Pep-
c19 
Previously, it was shown that 30K proteins do not show any toxic effect in 
vitro cell cultures and in vivo study [10, 13, 16, 17, 139]. To examine in vivo 
toxicity of Pep-c19, we measured the toxicity parameters that represent toxicity 
in kidney and liver. Toxicity in kidney is shown by increase in the levels of 
blood urea nitrogen (BUN) and creatinine, whereas toxicity on liver is shown 
by increase in the levels of aspartate aminotransferase (ALT) and alanine 
aminotransferase (AST) [159, 160]. The level of BUN, creatinine, ALT and 
AST from the blood serum of Pep-c19-injected mice were analyzed by Neodin 
Institute. We injected 3 different mice with 0.2 mol/kg and 2 mol/kg of each 
protein, every day, for 14 days, and evaluated the toxicity. After 2 weeks of 
injection, no apparent differences in the body weights and behaviors of mice 
were observed in any of the groups (data not shown). Toxicity results showed 
that high dose and long-term administration of Pep-c19 did not cause 
statistically significant or meaningful differences between 30Kc19 protein and 
Pep-c19 from all four toxicity parameters (Figure 6.4). In all tests, the p-values 
between the control group and the 30Kc19-injected group and Pep-c19-injected 
group were mostly higher than 0.1. These results indicate that long-term 
administration of Pep-c19 did not cause significant toxicity in vivo. Previously, 
it was reported that Tat and VP22 are non-toxic both in vitro [51, 161, 162] and 
Tat is non-toxic in vivo [92]. In another group, toxicity was evaluated in vivo by 





Figure 6.3.1 In vivo delivery of GFP into various tissues by Pep-c19. Proteins 
were dissolved in PBS with 10 mg/ml, 20 mg/mg, 10 mg/ml, respectively, and 
were intraperitoneally injected into female 5-week-old ICR mice (25 g). Same 
molar amount of GFP, GFP-30Kc19, and GFP-Pep-c19 were injected into mice 
(3.5 mol/kg; 100 mg/kg mouse for GFP, 200 mg/kg mouse for GFP-30Kc19, 
100 mg/kg mouse for GFP-Pep-c19). As a control experiment, the same volume 
of PBS was injected into mice. After 12 h of injection, the organs; heart, lung, 
kidney, and liver were collected, and tissues were sectioned to 10 m width 
using a microtome-cryostat. The penetrated GFP-Pep-c19 was visualized by 





Figure 6.3.2 In vivo delivery of GFP into brain tissues by Pep-c19. Proteins 
were dissolved in PBS with 10 mg/ml, 20 mg/mg, 10 mg/ml, respectively, and 
were intraperitoneally injected into female 5-week-old ICR mice (25 g). Same 
molar amount of GFP, GFP-30Kc19, and GFP-Pep-c19 were injected into mice 
(3.5 mol/kg; 100 mg/kg mouse for GFP, 200 mg/kg mouse for GFP-30Kc19, 
100 mg/kg mouse for GFP-Pep-c19). As a control experiment, the same volume 
of PBS was injected into mice. After 12 h of injection, the brain was collected, 
and tissues were sectioned to 10 m width using a microtome-cryostat. The 
penetrated GFP-Pep-c19 was visualized by GFP fluorescence (Green), and 





concentrations, the Antennapedia peptide showed no toxicity, whereas Tat 
caused some mild eyelid swelling [163]. The results in Figure 6.4 show that 
Pep-c19 has similar non-toxic property. Therefore, it is anticipated that Pep-c19 
could be utilized as an efficient and nontoxic carrier for the delivery of 
biological molecules into tissues in vivo. Other than fusing the CPP with the 
cargo, the non-conjugation approach may also be adapted for the delivery of 
cell-impermeable cargos; for instance siRNA, by mixing the CPP and siRNA 
and forming CPP/siRNA complex. 
  Regarding the mechanism of entry for 30Kc19 and Pep-c19, it was found that 
Cys-57 plays a crucial role in the dimerization and penetration. Because Cys-57 
is the final jigsaw puzzle of the Pep-c19 sequence, the mode of penetration is 






Figure 6.4 Toxicity test for the long-term administration of Pep-c19. 30Kc19 
and Pep-c19 were injected to mice daily (0.2 mol/kg and 2 mol/kg) for 14 
days. For the control experiment, the same volume of PBS was injected. 3 
different mice were used for each experiment (n = 3). To evaluate serum 
biological parameters, blood serum were collected from mice. (a), (b) To 
analyze the kidney function, blood urea nitrogen (BUN) and creatinine levels 
were determined. (c), (d) As a parameter of the liver function, aspartate 
aminotransferase (AST) and alanine aminotransferase (ALT) activities were 
determined. The p-values on each bar were evaluated by comparing with the 





 The newly identified CPP; VVNKLIRNNKMNC, from 30Kc19 protein was 
analyzed for its ability to penetrate and deliver cargo molecules in vitro and in 
vivo. In this study, Pep-c19 was fused to the C-terminal of the cargo protein and 
intracellular delivery was successful. But similar intracellular delivery is 
expected if Pep-c19 is located at N-terminal of the cargo protein. When Pep-c19 
was intraperitoneally injected into mice, Pep-c19 successfully delivered cargo 
proteins into various organ tissues with higher efficiency than the 30Kc19 
protein itself, and without toxicity in kidney and liver. However, no 
fluorescence was detected for all groups in the brain tissue, indicating the both 
the 30Kc19 and Pep-c19 are unable to penetrate and deliver cargos across the 
blood brain barrier (BBB). In any case, results strongly suggest that Pep-c19 
could be utilized as an efficient and nontoxic carrier for the delivery of 
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Chapter 7. In vitro siRNA delivery system using cell-
penetrating peptide of the 30Kc19 protein (Pep-c19) 
7.1 Introduction 
  In 1998, Andrew Fire first discovered RNA interference (RNAi) and since 
then it has now spread to become a standard protocol [164]. RNAi responses 
are initiated by delivery of short sequence of nucleotides called “short 
interfering RNAs (siRNAs)” into the cytoplasm of cells. Cytoplasmic siRNAs 
then combine with RNA-induced silencing complex (RISC) which then 
recognizes and degrades target mRNAs [165] (Figure 7.1). However, due to 
their size (larger than 10 kDa) and strong negative charge, siRNAs cannot enter 
cells on their own and therefore require a delivery vehicle. Although many 
materials, such as cationic lipids and polymers have been developed to deliver 
siRNAs, these delivery agents cannot introduce siRNAs into the entire 
population of cells and in a non-cytotoxic fashion, especially primary cells. 
Hence, siRNA delivery into cells remains the rate-limiting step problem for 
development of RNAi.  
These siRNAs can be beneficial for modulating expression of specific gene 
of interest with treatment of diseases such as viral infection, cancer, and genetic 
disorders [164, 166-169]. In clinical practice, however, therapeutic application 
of siRNA has been hindered due to limited stability, poor cellular uptake in vivo, 
and lack of a reliable delivery method [170-172]. The main obstacle in practical 
application of siRNA as a molecular medicine is the where it can lead 





Figure 7.1 Principle of RNAi. RNAi are long double-stranded RNA (dsRNA) 
molecules complementary to mRNA sequences. When siRNAs enter the cell, 
RISC-siRNA complex forms which can induce suppression of specific genes of 




without the use of transfection reagents or techniques that may damage the 
plasma membrane. Adenoviruses, liposomes, and cationic polymers can be 
useful delivery systems [174-177]. Viral vector-based siRNA delivery 
overcomes the problem of poor transfection, but clinical application of viral 
vectors is hampered by concerns about serious inflammatory side effects [175, 
177, 178]. Conjugating or entrapping the siRNAs to or in a nano-carrier such as 
a water soluble polymer, cationic lipid, or liposome is less toxic than use of 
viral vectors. However, there are still problems of low efficiency, and the 
siRNAs have to escape the endosome [174, 176]. Therefore, search for a safe 
and highly effective delivery system for siRNA-based molecular medicine 
continues. With this in mind, a new approach using ‘‘cell penetrating peptide 
(CPP)’’ for systemic siRNA delivery seems promising. 
Some researchers have reported that the formation of covalently bound 
conjugates between CPPs and siRNA offers another potential delivery strategy. 
For this strategy to work, a CPP [179-181], transportan [180], or Tat [103, 181] 
should be linked to a siRNA. However, the binding of CPPs to siRNA is 
difficult [182]. 
Another proposed method is the formation of non-covalent electrostatic 
bonds between siRNA and CPPs, including arginine-rich peptides [183, 184], 
MPG peptide [185] and its analogue [102], and penetratin analogue [186].  
The preparation of such CPP-siRNA complexes is technically simple, because 
these are formed through electrostatic interaction in an aqueous solution which 
requires no purification. Although some researchers have demonstrated 




complexes may reduce the penetration efficiency of CPPs.  
To address the siRNA delivery problem, Pep-c19 CPP was used because 
previously CPPs was shown to rapidly transport macromolecules into the entire 
population of cells in a non-cytotoxic manner via macropinocytosis, a 
specialized type of fluid phase endocytosis that all cells appear to perform [187]. 
Here, the cell-penetrating peptide of 30Kc19 protein (Pep-c19), originating 
from the silkworm for the delivery of siRNA is presented. Through non-
covalent biding between the Pep-c19 and siRNA, Pep-c19/siRNA complex was 
formed for its gene silencing effect in comparison with a well-known CPP, 11R. 
The cargo delivery efficiency as well as cytotoxicity of the CPP/siRNA 
complexes were determined in vitro. 
 
7.2 Formation of non-covalent CPP/siRNA complexes 
  Non-covalent CPP/siRNA complexes were made by mixing CPP and siRNA 
together and incubated for 15 min at room temperature. 0.5 g of siRNA was 
used and molar excess CPPs were mixed. 2% (w/v) agarose gel in TAE buffer 
was used for gel shift/retardation assay and electrophoresis was conducted. The 
siRNA began to disappear at 20-fold molar excess for 11R and 50-fold molar 
excess Pep-c19 (Figure 7.2). This demonstrated that 11R forms 11R/siRNA 
complex at lower molar excess than the Pep-c19/siRNA. The reason being 
could be because 11R is more positively charged than the Pep-c19 due to the 
presence of more positive-charged amino acids (Arginine) than the Pep-c19, 






Figure 7.2 Gel shift/retardation assay for CPP to form complexes with siRNA. 
0.5 g of siRNA was used and molar excess CPPs were mixed and incubated 
for 15 min at room temperature for the formation of CPP/siRNA complex. 2% 






7.3 Internalization of non-covalent CPP/siRNA complexes 
in HeLa cells 
  Internalization of non-covalent CPP/siRNA complexes was analyzed in HeLa 
cells. HeLa cells were seeded on 24 well and 20- and 50-fold molar excess 
CPPs to 100 nM siRNA were preincubated for the formation of CPP/siRNA 
complex. CPP/siRNA complexes were added to the culture medium and 
incubated for 1 h at 37 °C in 5% CO2. Cells were thoroughly washed 3 times 
with PBS and any non-specific binding to the membrane was removed by 
trypsin treatment. Cells were collected, lysed with RIPA buffer, and the lysate 
was analyzed for the presence of Cy3, linked to 3´end of siRNA. Fluorescence 
was analyzed using spectrofluorometer (ex 535 nm, em 612 nm) and then it was 
normalized to the total protein amount of cells. The fluorescence of internalized 
Pep-c19/siRNA complex was 2.3 fold and 3.5 fold higher than the siRNA, as 
compared with 2.1 fold and 1.68 fold higher for 11R/siRNA, the former 20-fold 
and latter 100-fold molar excess of CPPs to siRNA, respectively (Figure 7.3). 
This demonstrated that Pep-c19 is more efficient in internalizing and delivering 
siRNA to cells than 11R CPP.  
 
7.4 Effect of CPP/siRNA complex on the fluorescence of 
HEK 293-EGFP cells 
  The gene silencing effect of internalized CPP/siRNA complexes were 
analyzed in HEK 293-EGFP cells. HEK 293-EGFP cells were seeded on 24 







Figure 7.3 Internalization of non-covalent CPP & siRNA-Cy3 complexes in 
HeLa cells. 100 nM siRNA was used. 2 and 10 M of CPPs were mixed with 
siRNA to form CPP/siRNA complexes by preincubating for 15 min at room 
temperature. CPP/siRNA complex was added to culture medium for 1 h and 
were washed vigorously with PBS. Trypsin was added to remove any prebound 
complexes to cell membrane. Cells were collected, lysed and cell lysate was 
analyzed for the presence of Cy3 using spectrofluorometer (Ex 535, Em 
612nm). Data were normalized to total protein amount of cells. Experiment was 






preincubated for the formation of CPP/siRNA complex. CPP/siRNA complexes 
were added to the culture medium and incubated for 24 h and 72 h at 37 °C in 5% 
CO2. Cells were thoroughly washed 3 times with PBS and any non-specific 
binding to the membrane was removed by trypsin treatment. Cells were 
collected, lysed with RIPA buffer, and the lysate was analyzed for the amount of 
EGFP by fluorescence. Fluorescence was analyzed using spectrofluorometer 
(ex 485 nm, em 535 nm) and then it was normalized to the total protein amount 
of cells. The fluorescence of EGFP in cells treated with 11R/siRNA complex for 
24 h was reduced 13.6% and 14.8% for 20-fold and 100-fold molar excess 
CPPs to siRNAs, respectively (Figure 7.4.1(a)). For Pep-c19/siRNA complex, 
the fluorescence of EGFP in cells was reduced 17.3% and 20.1% for 20-fold 
and 100-fold molar excess CPPs to siRNAs, respectively. However, the 
fluorescence of EGFP in cells treated with 11R/siRNA complex for 72 h was 
reduced 18.9% and 17.8% for 20-fold and 100-fold molar excess CPPs to 
siRNAs, respectively (Figure 7.4.1(b)). For Pep-c19/siRNA complex, the 
fluorescence of EGFP in cells was reduced 17.7% and 18.2% for 20-fold and 
100-fold molar excess CPPs to siRNAs, respectively. This demonstrated that 
Pep-c19 and 11R have similar gene silencing effect in cells. This was verified 
again by Western blot were for 72 h were thoroughly washed 3 times with PBS 
and any non-specific binding to the membrane was removed by trypsin 
treatment. Cells were collected, lysed with RIPA buffer, and the lysate was 
analyzed for the amount of EGFP by Western blot analysis (Figure 7.4.2 (a)).  
tubulin was used as standard. For 11R/siRNA treated cells, no comparative 






Figure 7.4.1 Gene silencing effect of non-covalent CPP-EGFP siRNAs 
delivered in HEK 293-EGFP cells. 100 nM siRNA was used. 2 and 10 M of 
CPPs were mixed with siRNA to form CPP/siRNA complexes. (a) 24 h (p  
0.01) and (b) 72 h (p < 0.05). Cells were collected, lysed and cell lysate was 
analyzed for the presence of EGFP using spectrofluorometer (ex 485, em 535 






Figure 7.4.2 Gene silencing effect of non-covalent CPP-EGFP siRNAs 
delivered in HEK 293-EGFP cells. 100 nM siRNA. 10 M of CPPs were mixed 
with siRNA to form CPP/siRNA complexes. 72 h. (a) Cell lysate was analyzed 
for the presence of EGFP using Western blot analysis. Primary antibodies are  
tubulin and EGFP antibody. Data were normalized to  tubulin content in cells. 
n = 2. (b) Western blot data was converted quantitatively by ImageJ. *p  0.25. 





However, for Pep-c19/siRNA treated cells showed lower amount of EGFP 
protein in cells, and 28% reduction was seen than the control (Figure 7.4.2 (b)). 
This data demonstrated that Pep-c19/siRNA complex has more gene silencing 
effect than 11R/siRNA complex in cells. 
 
7.5 Cytotoxicity of CPP/siRNA complex 
The cytotoxicity of internalized CPP/siRNA complexes was analyzed in 
HEK 293-EGFP cells. HEK 293-EGFP cells were seeded on 24 well and 20- 
and 100-fold molar excess CPPs to 100 nM siRNA were preincubated for the 
formation of CPP/siRNA complex. CPP/siRNA complexes were added to the 
culture medium and incubated for 24 h and 72 h at 37 °C in 5% CO2. Cells were 
thoroughly washed 3 times with PBS. Then 0.5 mg/ml MTT (3,(4,5-
dimethylthiazol-2-yl)2,3-diphenyltetrazolium) was added to the media and 
incubated for 2 h. The formazan crystals that developed were solubilized with 
dimethyl sulfoxide (SigmaAldrich), and absorbance was measured at 560 nm 
using the ELISA reader. The viability of cells treated with 11R/siRNA complex 
for 24 h was reduced 89.0% and 84.6% for 20-fold and 100-fold molar excess 
CPPs to siRNAs, respectively (Figure 7.5(a)). For Pep-c19/siRNA complex, the 
viability of cells was reduced 96.2% and 88.9% for 20-fold and 100-fold molar 
excess CPPs to siRNAs, respectively. For 72 h incubation, the viability of cells 
treated with 11R/siRNA complex was reduced 88.6% and 77.5% for 20-fold 
and 100-fold molar excess CPPs to siRNAs, respectively (Figure 7.5(b)). For 
Pep-c19/siRNA complex, the viability of cells was reduced 82.9% and 80.8% 




demonstrated that Pep-c19 and 11R have similar cytotoxicity in cells and more 
cytotoxicity was seen for longer period of incubation for 72 h than 24 h. 
With regards to cell penetration, cell-penetrating mechanism of Pep-c19 is 
thought to be similar with 30Kc19 protein as mentioned previously, hence is 
expected to form a dimer at the cell membrane during penetration. When siRNA 
is mixed with Pep-c19, a non-covalent CPP/siRNA complex is formed prior to 
internalization. Thus, for Pep-c19/siRNA complex, it is thought to form a dimer 







Figure 7.5 Cytotoxicity of non-covalent CPP-EGFP siRNAs delivered in HEK 
293-EGFP cells. 100 nM siRNA. 2 and 10 M of CPPs were mixed with siRNA 
to form CPP/siRNA complexes. (a) 24 h and (b) 72 h. Then 0.5 mg/ml MTT 
was added to the media. The formazan crystals that developed were solubilized 
with, and absorbance was measured at 560 nm using the ELISA reader. n = 3. (a) 
For 24 h, #p < 0.05 and the rest of the groups have p  0.5. (b) For 72 h, #p < 






The newly identified CPP; VVNKLIRNNKMNC, from 30Kc19 protein was 
analyzed for its ability to penetrate and deliver cargo molecules in vitro by non-
covalent method. When compared with the conjugated approach, the method 
itself is easier as mixing between the cargo and CPP is all that is needed prior to 
the addition to cell culture media. However, limitation lies in that cargo has to 
have negative charge for Pep-c19 to form a CPP/siRNA complex like other 
CPPs, such as 11R. Similar gene silencing effect was seen for Pep-c19 and 11R, 
and slight cytotoxicity was seen for both CPP/siRNA complexes when treated 
for longer period of time (72 h). The results strongly suggest that Pep-c19 has a 
great potential for the efficient delivery of siRNA in vitro, however, further 
study needs to be carried out for its applicability in vivo. Moreover, it would be 
interesting to perform conjugation approach, as to which method is more 
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Chapter 8. Overall discussion and further suggestions 
8.1 Overall discussion 
Several studies have examined the functional properties for 30Kc6 and 
30Kc19, and it was demonstrated that silkworm hemolymph and 30K proteins 
exhibit an anti-apoptotic effect in various cells by adding the protein to culture 
or medium by gene expression. 30K proteins also enhanced productions of 
recombinant erythropoietin, interferon-, and monoclonal antibody, as well as 
increasing glycosylation, cell growth, and viability in various cells, and also had 
enzyme-stabilizing effects.  
Due to many phenomenal effects of the 30K proteins, mass production of the 
proteins was desired and thus E. coli was selected as host for recombinant 
protein expression. However, difficulty lied for the 30Kc6 protein, an anti-
apoptotic protein, because it was expressed as inclusion bodies. Generally, 
inclusion bodies are not sought because the misfolded proteins require refolding 
into bioactive forms, which are time-consuming and economically not viable. 
Hence, soluble forms of proteins are preferred over insoluble proteins. This is 
where the 30Kc19 comes in. Recently, the 30Kc19 protein has been studied in a 
great deal because it is expressed as soluble form in E. coli. Getting in hold of a 
large quantity of soluble recombinant 30Kc19 protein was definitely useful 
because it enabled researchers to perform numerous experiments on finding out 
the actual role and function of the protein.  
This was the reason why the 30Kc19 protein was chosen as the raw material 




(30Kc6, 30Kc12, 30Kc19, 30Kc21 and 30Kc23), was reported to be the most 
abundant among 30K proteins in the hemolymph of Bombyx mori. In the 5th 
instar larva to early pupa stage, these 30K proteins are synthesized in fat body 
cells and accumulate in the hemolymph. They are then transferred from the 
hemolymph to fat body cells during metamorphosis from larva to pupa, and are 
deposited there until later use. Then it came as a wonder why the 30Kc19 was 
vastly available in the silkworm hemolymph and why it was in the form of 
soluble protein. Only recently, the biological functions of the 30Kc19 protein 
started to unravel.   
A recent study has shown that 30Kc19 protein has a cell-penetrating property 
when supplemented to the culture medium. In accordance with previous 
research, the 30Kc19 protein was found to be a very unique multi-functional 
protein. However, the exact mechanism of penetration to animal cells had not 
been fully determined and hence was necessary to understand the molecular 
mechanism of cell penetration for the practical use of the 30Kc19 protein. In 
parallel with the cell-penetrating property, dimerization propensity was seen for 
the 30Kc19 protein in the presence of sodium dodecyl sulfate (SDS). Native 
PAGE was carried out and showed that the 30Kc19 monomer formed a dimer 
when SDS or phospholipid was present. This dimerization phenomenon of the 
30Kc19 protein in the presence of amphiphilic moieties; SDS or phospholipid, 
was key to explanation of the mechanism of entry. This led to perform GST 
pull-down assay, where supplementation of the 30Kc19 protein to mammalian 
cell culture medium showed dimerization and penetration; due to phospholipids 




analysis, it was certain that the 30Kc19 protein formed dimer at phospholipid of 
the cell membrane and thus the 30Kc19 protein existed as dimer inside the cell. 
However, how the 30Kc19 protein homodimerizes during penetration was still 
unsure. A similar result was demonstrated with the peptide hormone resistin in 
which a disulfide-linked homodimer was converted to a monomer under 
reducing conditions and conversion of a single cysteine to alanine abolished the 
dimerization. Thus, mutagenesis was performed, and penetration was observed 
by 30Kc19 C76A and not 30Kc19 C57A, which meant Cys-57 is involved in 
dimerization of the 30Kc19 at the cell membrane during penetration. 
Based on the cell-penetrating mechanism and cargo-delivering ability, 
hypothetical presence of cell-penetrating peptide (CPP) was assumed and 
strived for the identification of a CPP of the 30Kc19 protein, originating from 
the silkworm. First, N- and C-terminal truncated forms of 30Kc19 protein were 
expressed and purified. When cells were incubated with soluble form of N-
terminal truncated 30Kc19 (30Kc191-120) at both 37 °C and 4 °C, 30Kc191-120 
protein was found in the cell. This confirmed that CPP exist in the N-terminal 
of the 30Kc19 protein. However, for the practical use in delivery of cell-
impermeable cargo molecules, the size of the truncated protein was still large. It 
was necessary to find a cell-penetrating domain, a minimal effective partial 
sequence of the parent cell-penetrating protein that can efficiently deliver cargo 
molecules into cells. A domain was selected as the most probable candidate 
from the result of helix motif, positive surface charge, hydrophobicity, and 
relative surface accessibility. The hydrophobic amino acid was thought to be an 




contains 6 hydrophobic amino (Ile, Ile, Trp, Phe, Met, Trp) acids in total. In 
addition, it was expected that cysteine may be an important factor because of 
previous report that it may be involved in the process of internalization via 
formation of dimer. Several CPP candidates were tested for cell-penetrating 
property and from this, a new CPP; VVNKLIRNNKMNC, from 30Kc19 
protein (Pep-c19) was identified. It demonstrated that 30Kc19 exhibited a cell-
penetrating property due to the presence of a cell-penetrating peptide at 45-57. 
On the other hand, other peptides; encompassing Val-41 and Ile-42 formed 
membrane-bound aggregates. The formation of aggregates could have risen 
from the hydrophobic amino acids in those peptides because of too many 
hydrophobic amino acids that allow stability and solubility in the culture 
medium. 
Then, the mode of intracellular penetration was evaluated by the use of 
inhibitors of endocytosis to find out how the Pep-c19 penetrates into cells. 
Sucrose was treated to give cells a hyperosmolar condition, but no markedly 
difference in the penetration ability of the Pep-c19 was seen. This showed that 
Pep-c19 does not penetrate by clathrin-mediated endocytosis. However, when 
cytochalasin B or nystatin was treated to cells, slightly lowered cell-penetrating 
ability of the Pep-c19 was seen, which demonstrates that it penetrates cells by 
macropinocytosis and caveolin-mediated endocytosis.  
Subsequently, Pep-c19 was compared with other CPPs. In terms of the 
primary structure, Pep-c19 CPP contains less positive amino acids (3 in the 
sequence) than other CPPs (TAT has 8, VP22 has 9, Antp; has 7). Instead, Pep-




CPPs (TAT has 0, VP22 has 1, Antp has 6). With the secondary structure, Antp’s 
homeodomain is comprised of 60 residues and it is consisted of 3 alpha-helices. 
Third alpha-helix is responsible for penetration (Antp), which is similar to our 
Pep-c19, because it is also from the third alpha helix of the 30Kc19 protein. 
HSV-1 protein has a size that is a little bigger than the 30Kc19 protein, 38 kDa, 
and VP22 is located at the very last 34 residues. These CPPs have been used to 
transduce proteins into cells and tissues and for some (Tat and Antp) even 
across blood brain barrier but efficiency various depending on the cargo that is 
attached to the CPPs. Whatever the differences are, among the CPPs, the major 
advantage of Pep-c19 is that it is not a virus-derived cell-penetrating peptide 
meaning it is applicable as a therapeutic tool, short length, and is not toxic. 
In addition, efficiency and toxicity of this CPP was investigated in 
comparison with its original protein, 30Kc19, both in vitro and in vivo and 
showed its superiority over its parent protein in terms of efficiency. However, 
cargo was delivered in all the tissues except the brain, isolated from the mice 
that were injected with GFP-30Kc19 or GFP-Pep-c19, although the 
fluorescence intensities varied among tissues. No fluorescence was detected for 
all groups in the brain tissue, indicating the both the 30Kc19 and Pep-c19 are 
unable to penetrate and deliver cargos across the blood brain barrier (BBB). 
Toxicity of Pep-c19 was tested in vivo, and measured the toxicity parameters 
that represent toxicity in kidney and liver. Toxicity in kidney is shown by 
increase in the levels of blood urea nitrogen (BUN) and creatinine, whereas 
toxicity on liver is shown by increase in the levels of aspartate aminotransferase 




dose and long-term administration of Pep-c19 did not cause statistically 
significant or meaningful differences between 30Kc19 protein and Pep-c19 
from all four toxicity parameter and demonstrated that Pep-c19 is non-toxic in 
vivo. Regarding the mechanism of entry for 30Kc19 and Pep-c19, it was found 
that Cys-57 plays a crucial role in the dimerization and penetration and because 
Cys-57 is the final jigsaw puzzle of the Pep-c19 sequence, the mode of 
penetration is expected to be similar for both cases. 
Finally, the Pep-c19 was used for therapeutic application; non-covalent 
approach for the delivery of siRNA was tested. The results showed that Pep-c19 
was able to deliver siRNAs and have gene silencing effect along with 11R, 
other widely recognized CPP. These results demonstrate that Pep-c19 can be 
applied for therapeutic applications. With regards to cell penetration, cell-
penetrating mechanism of Pep-c19 is thought to be similar with 30Kc19 protein 
as mentioned previously, hence is expected to form a dimer at the cell 
membrane during penetration. When siRNA is mixed with Pep-c19, a non-
covalent CPP/siRNA complex is formed prior to internalization. However, for 
Pep-c19/siRNA complex, it is thought to form a dimer with one another by Pep-
c19. 
The 30Kc19 protein and Pep-c19 are a non-virus derived (e.g. TAT) and non-
cytotoxic (polyarginine) cell-penetrating protein/peptide. The protein 
transduction method is advantageous over virus-based method in that it does 
not cause tumorigenicity, because genetic modification of host cells does not 
occur and permanent expression can be solved. This study may open up new 




bioindustries, such as pharma- and cosmeceuticals. 
 
8.2 Conclusion and further suggestions 
In this work, cell-penetrating mechanism was studied for the 30Kc19 protein 
when supplemented to the culture medium. In accordance with previous 
research, the 30Kc19 protein was found to be a very unique multi-functional 
protein. However, the exact mechanism of penetration to animal cells had not 
been fully determined and hence was necessary to understand the molecular 
mechanism of cell penetration for the practical use of the 30Kc19 protein. In 
parallel with the cell-penetrating property, dimerization propensity was seen for 
the 30Kc19 protein in the presence of amphiphilic moieties; SDS or 
phospholipid, which was the key to explanation of the mechanism of entry. 
Through further analysis, the results showed that the 30Kc19 protein formed 
dimer at phospholipid of the cell membrane and thus the 30Kc19 protein 
existed as dimer inside the cell. This was resolved by mutagenesis. Penetration 
was observed by 30Kc19 C76A and not 30Kc19 C57A, which meant Cys-57 is 
involved in dimerization of the 30Kc19 at the cell membrane during penetration. 
Based on the cell-penetrating mechanism and cargo-delivering ability, 
hypothetical presence of cell-penetrating peptide (CPP) was assumed. Even for 
the practical use in delivery of cell-impermeable cargo molecules, the size of 
the whole protein was still large. Through multiple analyses, a minimal 
effective partial sequence of the parent cell-penetrating protein that can 
efficiently deliver cargo molecules into cells was found. A new CPP; 




demonstrated that 30Kc19 exhibited a cell-penetrating property due to the 
presence of a cell-penetrating peptide at 45-57.  
Then, the mode of intracellular penetration was evaluated. Sucrose was 
treated to give cells a hyperosmolar condition, but no markedly difference in the 
penetration ability of the Pep-c19 was seen. This showed that Pep-c19 does not 
penetrate by clathrin-mediated endocytosis. However, when cytochalasin B or 
nystatin was treated to cells, slightly lowered cell-penetrating ability of the Pep-
c19 was seen, which demonstrates that it penetrates cells by macropinocytosis 
and caveolin-mediated endocytosis.  
The efficiency and toxicity of this CPP was investigated in comparison with 
its original protein, 30Kc19, both in vitro and in vivo and showed its superiority 
over its parent protein in terms of efficiency. However, cargo was delivered in 
all the tissues except the brain, isolated from the mice that were injected with 
GFP-30Kc19 or GFP-Pep-c19, although the fluorescence intensities varied 
among tissues. No fluorescence was detected for all groups in the brain tissue, 
indicating the both the 30Kc19 and Pep-c19 are unable to penetrate and deliver 
cargos across the blood brain barrier (BBB). Toxicity of Pep-c19 was tested in 
vivo, and measured the toxicity parameters that represent toxicity in kidney and 
liver and showed that high dose and long-term administration of Pep-c19 did 
not cause statistically significant or meaningful differences between 30Kc19 
protein and Pep-c19 from all four toxicity parameter and demonstrated that 
Pep-c19 is non-toxic in vivo. 
The Pep-c19 was used for therapeutic application; non-covalent approach for 




siRNAs and have gene silencing effect along with 11R, other widely recognized 
CPP. The protein transduction method is advantageous over virus-based method 
in that it does not cause tumorigenicity, because genetic modification of host 
cells does not occur and permanent expression of reprogramming factors can be 
solved. 
In terms of the primary structure, when Pep-c19 is compared with other CPPs, 
it contains less positive amino acids (3 in the sequence) than other CPPs (TAT 
has 8, VP22 has 9, Antp; has 7). Instead, Pep-c19 has more hydrophobic acids 
(6 in the sequence) than the most of other CPPs (TAT has 0, VP22 has 1, Antp 
has 6). With the secondary structure, Antp’s homeodomain is comprised of 60 
residues and it is consisted of 3 alpha-helices. Third alpha-helix is responsible 
for penetration (Antp), which is similar to our Pep-c19, because it is also from 
the third alpha helix of the 30Kc19 protein. These CPPs have been used to 
transduce proteins into cells and tissues and for some (Tat and Antp) even 
across blood brain barrier but not Pep-c19. Whatever the differences are, among 
the CPPs, the major advantage of Pep-c19 is that it is not a virus-derived cell-
penetrating peptide meaning it is applicable as a therapeutic tool, short length, 
and is not toxic. Unlike other CPPs, Pep-c19 cannot go across the BBB, hence 
can be applicable for delivery of cargos into other parts of the organs and not 
the brain. 
30Kc19 protein, among the 30K proteins (30Kc6, 30Kc12, 30Kc19, 30Kc21 
and 30Kc23), was reported to be the most abundant among 30K proteins in the 
hemolymph of Bombyx mori. In the 5th instar larva to early pupa stage, these 




hemolymph. They are then transferred from the hemolymph to fat body cells 
during metamorphosis from larva to pupa, and are deposited there until later use. 
It came as a wonder why the 30Kc19 was vastly available in the silkworm 
hemolymph and why it was in the form of soluble protein. Moreover, the cell-
penetrating property and enzyme-stabilizing properties have now come to be 
important in the development of silkworm. With the start of metamorphosis 
from larvae to pupae, 30K proteins are translocated from the hemolymph to fat 
body cells, which was recently unraveled. Only recently, the biological 
functions of the 30Kc19 protein started to unravel. Metamorphosis is a very 
intense process which is achieved in a very short period of time and thus a high 
number of enzymatic reactions occur simultaneously at once. Therefore, it is 
believed that cell-penetrating peptide within the 30Kc19 protein enables quick 
and steady penetration, and the enzyme-stabilizing property of the 30K19 
enables and maintains steady metabolism during the metamorphosis. 
The 30Kc19 protein and Pep-c19 are a non-virus derived (e.g. TAT) and non-
cytotoxic (polyarginine) cell-penetrating protein/peptide that is naturally found 
in nature. That may be the reason why cytotoxicity was not observed. From the 
identification Pep-c19, peptide engineering can be performed in relationship 
with other CPPs and further optimized Pep-c19 in terms of cell-penetrating and 
cargo-delivery efficiencies can be anticipated. In all, this study may open up 
new approaches and provide beneficial effects for the delivery of therapeutics in 
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30Kc19 단백질의 세포투과 펩타이드 동정과 특성 
분석 및 단백질과 유전자 전달을 위한 응용 
 
 





30Kc19 단백질은 누에 체액에 존재하는 유사한 구조의 단백질의 모임인 
30K 단백질 그룹의 일원이다. 이 단백질들은 30 kDa 정도의 분자량을 
지니며, 30Kc19 단백질은 누에 채액 내에 존재하는 30K 단백질들 (30Kc6, 
30Kc12, 30Kc19, 30Kc21, 30Kc23) 중 가장 많은 비중을 차지한다. 30K 
단백질의 누에 내 생물학적인 기능은 완벽히 알려지지 않았으나, 최근 
30Kc6와 30Kc19의 기능적 특성을 밝히는 연구들이 수행된 바 있다. 
이전의 연구에서, 누에 체액과 30K 단백질은 단백질을 배양 배지에 첨가 
혹은 30K 단백질 유전자를 발현하는 방법으로 여러 종류의 세포에서 항 
아폽토시스 효과를 나타냄을 보였다. 또한, 30K 단백질은 재조합 
에리스로포이에틴, 인터페론-, 단클론 항체의 생산량과 당쇄화를 
증대시키고, 여러 세포에서 세포 성장 및 생존을 증대시켰으며, 효소 안정화 




첨가될 경우, 세포투과 효과를 보임을 밝히기도 하였다. 따라서, 30Kc19 
단백질은 매우 독특한 특성을 지니는 다기능 단백질이며, 세포막을 투과하고 
운반한 단백질을 안정시킬 수 있기 때문에 효소를 포함한 치료용 단백질의 
전달에 활용될 수 있다.  
이 연구의 목적은 30Kc19 단백질의 이합체화 경향 및 세포투과 기작 
연구와 목적 물질을 운반하는 데 필요한 30Kc19 단백질내의 세포투과 
펩타이드를 찾는 것이다. 먼저, 양친성 물질, 즉 SDS 혹은 인지질 존재 
하에서의 30Kc19 단백질의 이합체화 경향을 연구하였다. Native 
폴리아크릴아미드겔전기영동 결과를 통하여 30Kc19 단량체가 SDS나 
인지질이 존재할 경우 이합체화가 되는 것을 보였다. GST pull-down 
분석을 통하여 동물 세포 배양 배지에 30Kc19가 첨가될 경우, 세포막에 
존재하는 지질 이중막의 주 성분인 인지질에 의하여 30Kc19가 이합체를 
형성하며 세포 내로 투과하는 것을 관찰할 수 있었다. 돌연변이 생성 수행 
결과 30Kc19 C76A에서 세포투과가 관찰된 반면 30Kc19 C57A에서는 
관찰되지 않았으며, 이는 Cys-57이 세포투과 과정 중 세포막에서 
이합체화가 되는 데 관여함을 의미한다. 다음으로는, 단백질 전달 시스템에 
이용하기 위하여 세포를 투과하는 30Kc19 단백질이 어떻게 주요 세포막 
구성 성분인 인지질과 연관되어 있는지 와 30Kc19 단백질이 동물 세포 
내로 진입하는 기작을 밝히는 연구가 진행되었다. 
세포투과 기작과 물질 수송 능력에 기반을 두어, 누에 유래 30Kc19 
단백질 내에 세포투과 펩타이드 (CPP) 가 존재할 것이라 가정하였고, 이를 
확인하기 위한 연구를 시도하였다. 실제로 세포를 투과할 수 없는 물질을 
세포 내에 전달하기 위해서는 30Kc19내에서 효율적인 물질 전달에 




필요하다. 30Kc19 내에서 가장 CPP일 가능성이 높은 후보 영역이 
선정되었으며, 여러 CPP 후보들의 세포투과 특성을 시험하였다. 이를 
통하여 30Kc19 내의 45-57번째 아미노산인 VVNKLIRNNKMNC 이 
새로운 CPP (Pep-c19) 로 규명되었다. 또한 이 CPP의 세포투과 효율과 
독성 여부를 30Kc19의 기능과 비교 실험한 결과, 생체외와 생체내 
모두에서 원 단백질에 비해 효율성이 우수함을 관찰하였다. 또한 치료 
목적으로의 응용을 위하여, siRNA 전달을 위한 비공유결합적 접근을 
시도하였다. 이 결과, Pep-c19이 siRNA를 세포 내로 성공적으로 운반하여, 
널리 사용되는 CPP인 11R을 사용하였을 때와 유사한 유전자 침묵화 
효과를 확인하였다. Pep-c19은 최초의 곤충 체액 유래의 세포투과 
단백질에서 얻은 세포투과 펩타이드이기 때문에, 이 발견을 통하여 다른 
곤충 유래의 단백질에서 Pep-c19과 유사한 특성을 갖는 다른 세포투과 
펩타이드를 발견할 수 있을 것으로 기대된다.  
30Kc19 단백질과 Pep-c19는 TAT와 달리 비-바이러스 유래 물질이며, 
세포 독성이 없는 세포투과 단백질/펩타이드로서 응용 가능하다. 이 연구를 
통하여 제약, 화장품과 같은 생물 산업에서의 효율적인 치료 물질 전달을 
위한 이로운 효과를 미치는 새로운 접근 방법을 열어 줄 수 있을 것으로 
기대된다. 
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